Document:

exv4w2

Exhibit 4.2

			
	[***]	 	Represents material which has been redacted and filed separately with the Commission
pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

STOCK PURCHASE AGREEMENT

     THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made by and between Remedent, Inc., a
Nevada corporation (“Remedent”), having a principal place of business at Xavier de Cocklaan 42,
9831 Deurle, Belgium and                      (the “Holder”), an individual having a principal place of
residence at                     , as of August 24, 2008 and to be effective on the closing of the
Den-Mat Agreement by Remedent as described below (the “Effective Date”).

RECITALS

     A. Holder owns seven hundred fifty (750) shares of common stock of Glamtech-USA, Inc., a
Delaware corporation (the “Shares”), together with the shares held by                      constituting one
hundred percent of the capital stock of Glamtech-USA, Inc. (“Glamtech”); and

     B. Concurrently with the execution of this Agreement, Remedent entered into a Distribution,
License and Manufacturing Agreement, dated August 24, 2008, by and among Remedent, Remedent, B.V.,
and Den-Mat Holdings, LLC (the “Den-Mat Agreement”) and a Rescission Agreement, dated as of even
date, with Glamtech.

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereby agree as follows:

     1. Purchase and Sale of the Shares. Subject to and upon the terms and conditions of
this Agreement, on the Effective Date, Holder shall sell, convey, assign, transfer and deliver to
Remedent, and Remedent shall purchase from Holder, all of the Shares.

     2. Purchase Price. In consideration for the aforesaid sale, conveyance, assignment,
transfer and delivery of the Shares to Remedent on the Effective Date, Remedent shall, upon the
election of the Holder at any time during the six month period following the Effective Date (the
“Holder Election”), issue to Holder either of the following (which shall be at the sole discretion
of Holder):

	 	(i)	 	500,000 shares of restricted common stock of Remedent (as
adjusted for combinations, consolidations, subdivisions, stock splits or
similar transactions) (the “Remedent Shares”); or
	 
	 	(ii)	 	a five (5) year warrant (the “Remedent Warrant”) to purchase
623,608 shares of Remedent’s restricted common stock (as adjusted for
combinations, consolidations, subdivisions, stock splits or similar
transactions) (the “Remedent Warrant Shares”) at an exercise price of $1.30 per
share, in the form attached hereto as Exhibit B.

From and after the Effective Date, Remedent shall also be obligated to pay to Holder the royalty
payments described in Section 5 below.

     3. Manner of Holder Election. Holder shall make the Holder Election by delivering to
Remedent a written notice stating the form of payment he wishes to receive in exchange for the
Shares as set forth in Section 2 above. Such notice shall be delivered to Remedent at the address
and in the manner provided in Section 12. Within three business days after delivery of such
notice, Remedent shall cause the Remedent Shares or the Remedent Warrants, as applicable, to be
issued in certificated form and delivered to the Holder at the address and in the manner provided
in Section 12.

 

 

     4. Registration Rights. Remedent shall cause the Remedent Shares or the Remedent
Warrant Shares, as applicable, to be registered pursuant to a registration statement (the
“Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) no
later than thirty (30) calendar days following the date of the Holder Election, but no sooner than
seventy-five (75) days from the Effective Date of this Agreement . Remedent shall use its best
efforts to cause the Registration Statement to be declared effective by the Commission no later
than (i) thirty (30) calendar days following the date of the registration statement is filed if
there is no Commission review of the Registration Statement and (ii) sixty (60) calendar days
following the date of the the registration statement is filed if there is Commission review of the
Registration Statement. Holder acknowledges and agrees that Remedent may satisfy its obligations
under this Section 4 by registering the Remedent Shares or the Remedent Warrant Shares, as
applicable, pursuant to an effective registration statement covering the resale by other holders of
the Company’s securities, so long as all of the Remedent Shares or Remedent Warrant Shares, as
applicable, held by Holder are registered.

     5. Royalty Payments. During the term of the Den-Mat Agreement, Remedent shall pay to
the Holder the payments specified in Exhibit A.

     6. Reports and Audits. Within thirty (30) days after the end of each quarter,
Remedent shall furnish to Holder a written report containing an accounting of the royalty fees
collected by Remedent from Den-Mat under the Den-Mat Agreement and for which royalties are payable
under this Agreement. Remedent’s royalty report shall be certified by an officer of Remedent.
Remedent shall keep records in sufficient detail to permit the determination of royalties payable
hereunder and at the request and expense of Holder will permit an independent auditor selected by
Holder to examine, during ordinary business hours once in each calendar year, such records and
other materials as may be required by the auditor to verify or determine royalties payable under
this Agreement. Such auditor shall be instructed to report to Holder only the amount of royalties
due and payable. If an audit identifies a shortfall in the amount of the royalties paid to Holder,
then Remedent agrees to promptly pay to Holder the amount of any such shortfall and, if the
shortfall is more than five percent (5%), to reimburse Holder for the costs it has incurred in
relation to such audit.

     7. Holder Representations, Warranties and Covenants.

          (a) Holder represents and warrants that, Holder holds of record and owns beneficially all of
the Shares, free and clear of any restrictions on transfer, taxes, security interests, options,
warrants, purchase rights, contracts, commitments, equities, claims and demands. As of the date of
this Agreement, the Holder is not a party to any option, warrant, purchase right, pledge agreement
or other contract or commitment that could require the Holder to sell, transfer or otherwise
dispose of the Shares, except as provided in this Agreement. Upon Remedent’s purchase of the
Shares under this Agreement, Remedent will obtain and be fully vested in record and beneficial
ownership of the Shares, free and clear of any restrictions on transfer (other than any
restrictions under the Securities Act and state securities laws), taxes, security interests,
options, warrants, purchase rights, contracts, commitments, equities, claims and demands.

          (b) Holder represents and warrants that as of the date of this Agreement, Holder and Doug Cox
own all of the shares of Glamtech, and to the best of Holder’s knowledge, there are no options or
obligations granted by Glamtech to purchase any shares of Glamtech.

2

 

     8. Remedent Representations and Warranties.

          (a) Remedent represents and warrants to Holder that Remedent has the requisite corporate power
and authority to enter into this Agreement and to consummate the transactions contemplated hereby.

          (b) Remedent represents and warrants to Holder that the Remedent Shares have been duly and
validly authorized and reserved for issuance and sale to the Holder pursuant to this Agreement and,
when issued and delivered by the Company in accordance with the terms of this Agreement, will be
duly and validly issued and fully paid and nonassessable, and will be sold free and clear of any
restrictions on transfer (other than any restrictions under the Securities Act and state securities
laws), taxes, security interests, options, warrants, purchase rights, contracts, commitments,
equities, claims and demands. Remedent represents and warrants to Holder that the Remedent
Warrant, when executed and delivered by Remedent in accordance with the terms of this Agreement,
will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms. Remedent represents and warrants to Holder that the Remedent Warrant
Shares have been duly and validly authorized and reserved for issuance and sale to the Holder and,
upon exercise of the Remedent Warrant in accordance with the terms thereof, including the payment
of any exercise price therefor, will be validly issued, fully paid and nonassessable and will be
sold free and clear of any restrictions on transfer (other than any restrictions under the
Securities Act and state securities laws), taxes, security interests, options, warrants, purchase
rights, contracts, commitments, equities, claims and demands.

     9. Entire Agreement. This Agreement (including the exhibits and schedules attached to
it) is the final expression of, and contains the entire agreement between, the parties with respect
to the subject matter of the Agreement and supersedes all prior and contemporaneous understandings
with respect to it.

     10. Modifications/Amendments. This Agreement may not be modified, amended,
supplemented, or terminated, nor may any obligations under it be waived, except by written
instrument signed by the party to be charged or by its agent duly authorized in writing or as
otherwise expressly permitted herein.

     11. Applicable Law. The parties acknowledge that this Agreement has been negotiated
and entered into in the State of California. The rights of the parties under this Agreement shall
be governed by and construed in accordance with the laws of the State of California, without regard
to its choice of law principles.

     12. Notices. Any notice or other communication required or permitted to be given
under the terms of this Agreement shall be in writing and as shall be deemed given if delivered or
sent by certified United States Mail, postage prepared, to the parties at their addresses as first
above noticed, or such other addresses shall be designated by written notice to the parties.
Notice shall be effective upon receipt or two (2) business days after mailing in the manner
provided above.

[SIGNATURE PAGE TO FOLLOW]

3

 

     IN WITNESS WHEREOF, this Stock Purchase Agreement is executed this 24th day of
August, 2008.

	 	 	 	 	 	 	 
	 	 	Holder	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	Remedent, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:	 	 	 	 

 

EXHIBIT A

ROYALTY PAYMENTS

[***]

5

 

EXHIBIT B

FORM OF WARRANT

[See attached]

 

THE SECURITIES REPRESENTED BY THIS WARRANT CERTIFICATE, INCLUDING THE UNDERLYING SECURITIES
ISSUABLE UPON EXERCISE HEREOF, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”) NOR WITH ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
ACT AND APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS OR (B) OR UPON RECEIPT BY THE ISSUER OF AN OPINION OF COUNSEL IN
SUCH FORM AS REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT SUCH TRANSFER IS EXEMPT FROM
REGISTRATION UNDER THE ACT AND SUCH STATE SECURITIES LAWS.

WARRANT CERTIFICATE

OF

REMEDENT, INC.

			
	Date of Issuance: August ___, 2008
	 	Certificate Number: ___

     THIS WARRANT CERTIFICATE (“Warrant Certificate”) certifies that, for value received,
                                        , an individual (the “Holder”), having his principal place of residence at
                                                            , is entitled to purchase at any time on or prior to the Expiration
Date (hereinafter defined), up to Six Hundred Twenty-Three Thousand Six Hundred Eight (623,608)
shares of Common Stock of Remedent, Inc., a Nevada corporation (the “Company”) at a purchase price
as set forth below, subject to adjustment as hereinafter provided.

     1. Warrant Purchase Price. Each Warrant shall entitle the Holder to purchase one
share of Common Stock and the purchase price payable upon exercise of one Warrant shall be $1.30
per share (“Purchase Price”). The Purchase Price and number of shares of Common Stock (“Warrant
Shares”) issuable upon exercise of each Warrant are subject to adjustment as provided in Section 6.

     2. Exercise of Warrant.

          (a) Method of Cash Exercise. The Warrants are exercisable, at the option of the
Holder, in whole or in part, at any time upon surrender of this Warrant Certificate to the Company
together with a duly completed Notice of Exercise, in the form attached hereto as Exhibit
A, and payment of an amount equal to the Purchase Price times the number of Warrants to be
exercised. Payment is not required if Warrant is exercised pursuant to a cashless exercise in
Section 2(b).

          (b) Cashless Exercise; Net Exercise Election. The Holder may elect to convert all or
a portion of this Warrant Certificate, without the payment by the Holder of any additional
consideration, by the surrender of this Warrant Certificate or any portion thereof to the Company,
with the net exercise election selected in the Notice of Exercise attached hereto as
Exhibit A duly executed by the Holder, into up to the number of Shares that is obtained
under the following formula:

X = Y (A-B)

     A

     Where:

	 	 	 	 	 	 	 
	 

	 	X
	 	=
	 	The number of Warrant Shares to be issued to the Holder.

1

 

	 	 	 	 	 	 	 
	 

	 	Y
	 	=
	 	The number of Warrant Shares purchasable under this Warrant Certificate, or if
only a portion of this Warrant Certificate is 
	 
	 	being exercised, the portion of this
Warrant Certificate being canceled (at the date of such calculation).
	 
	 

	 	A
	 	=
	 	the average of the closing bid prices for the ten most
recent business days preceding the date of exercise on which the Common Stock
of the Company has traded on the primary exchange or market on which it is
listed.
	 
	 	 	 	 	 	 
	 

	 	B
	 	=
	 	The Purchase Price (as adjusted to the date of such calculations).

     3. Expiration. The term “Expiration Date” shall mean 5:00 p.m. (PST) on the fifth
(5th) anniversary of the Date of Issuance. If such date shall be a holiday or a day on
which banks are authorized to close, then 5:00 p.m. (PST) the next following date which is not a
holiday or a day on which banks are not authorized to close.

     4. Agreement of Holder. The Holder acknowledges that the Warrants represented by this
Warrant Certificate have not been registered under the Act and accordingly that they will not be
transferred or sold except pursuant to an effective registration statement under the Act or an
exemption therefrom, or in a transaction not subject thereto, and in compliance with all state
securities laws.

     5. Loss or Mutilation. Upon receipt by the Company of reasonable evidence of the
ownership of and the loss, theft, destruction or mutilation of this Warrant Certificate and, in the
case of loss, theft or destruction, of indemnity reasonably satisfactory to the Company, or, in the
case of mutilation, upon surrender and cancellation of the mutilated Warrant Certificate, the
Company shall execute and deliver in lieu thereof a new Warrant Certificate representing an equal
number of Warrants.

     6. Adjustment of Purchase Price and Number of Warrant Shares. The number and kind of
Warrant Shares purchasable upon the exercise of the Warrants and the Purchase Price shall be
subject to adjustment from time to time upon the occurrence of certain events, as follows:

          (a) Splits, Combinations, Reclassifications. In the event the Company shall (i) pay a
dividend in shares of Common Stock or make a distribution in shares of Common Stock to the holders
of the outstanding shares of Common Stock, (ii) subdivide its outstanding shares of Common Stock
through stock split or otherwise, (iii) combine its outstanding shares of Common Stock into a
smaller number of shares of Common Stock, or (iv) issue by reclassification of its Common Stock
(including any such reclassification in connection with a consolidation or merger in which the
Company is the continuing corporation) other securities of the Company, the number and/or nature of
Warrant Shares purchasable upon exercise of each Warrant immediately prior thereto shall be
adjusted so that the Holder shall be entitled to receive the kind and number of Warrant Shares or
other securities of the Company which it would have owned or have been entitled to receive after
the happening of any of the events described above, had such Warrant been exercised immediately
prior to the effective date of such event or any record date with respect thereto.

          (b) Reorganizations, Mergers, Consolidations or Sales of Assets. In the event of any
capital reorganization or any reclassification of the capital stock of the Company or in case of
the consolidation or merger of the Company with another corporation (other than a consolidation or
merger in which the outstanding shares of the Company’s Common Stock are not converted into or
exchanged for other rights or interests), or in the case of any sale, transfer or other disposition
to another corporation of all or substantially all the properties and assets of the Company, the
Holder of each Warrant shall thereafter be entitled to purchase (and it shall be a condition to the
consummation of any such reorganization, reclassification, consolidation, merger, sale, transfer or
other disposition that appropriate provisions shall be made so that such Holder shall thereafter be
entitled to purchase) the kind and amount

2

 

of shares of stock and other securities and property (including cash) which the Holder would
have been entitled to receive had such Warrants been exercised immediately prior to the effective
date of such reorganization, reclassification, consolidation, merger, sale, transfer or other
disposition.

          (c) Notice of Capital Changes. If at any time the Company shall effect any of the
events described in subsections (a) and (b) above, or there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Company, then, in any one or more of said cases, the
Company shall give the Holder written notice, by registered or certified mail, postage prepaid, of
the date on which (i) a record shall be taken for such dividends, distributions and the like or
(ii) such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation
or winding up shall take place, as the case may be. Such written notice shall be given at least
five business (5) days prior to the relevant event.

          (d) Adjustment of Purchase Price. Upon each adjustment in the number of Warrant
Shares purchasable hereunder, the Purchase Price shall be proportionately increased or decreased,
as the case may be, in a manner that is the inverse of the manner in which the number of Warrant
Shares purchasable hereunder shall be adjusted, as determined in good faith by the Board of
Directors of the Company.

          (e) Certificates of Adjustments. Whenever the Purchase Price or the number of Warrant
Shares purchasable hereunder shall be adjusted pursuant to this Section 6, the Company shall
prepare a certificate signed by the Chief Financial Officer of the Company setting forth, in
reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by
which such adjustment was calculated, and the Purchase Price and the number of Warrant Shares
purchasable hereunder after giving effect to such adjustment, and shall cause copies of such
certificate to be mailed, by first class mail, postage prepaid, to the Holder.

     7. No Voting Rights. Except as otherwise provided herein, this Warrant Certificate
shall not be deemed to confer upon the Holder any right to vote or to consent to or receive notice
as a shareholder of the Company, in respect of any matters whatsoever, prior to the exercise
hereof.

     8. Legends. This Warrant and the Warrant Shares (and the securities issuable,
directly or indirectly, upon conversion of the Warrant Shares, if any) shall be imprinted with a
legend in substantially the following form:

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE
AND, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED
UNLESS AND UNTIL REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAW OR,
IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF
THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT
FROM REGISTRATION.

     9. Warrants Transferable. Subject to the provisions of Section 9, this Warrant
Certificate and all rights hereunder are transferable, in whole or in part, at the principal
offices of the Company by the Holder hereof, upon surrender of this Warrant Certificate properly
endorsed; provided, however, that without the prior written consent of the Company,
this Warrant Certificate and all rights hereunder may be transferred only to (i) an affiliate of
the initial Holder hereof or successor in interest to any such person, or (ii) pursuant to the
registration of the Warrants or the Warrant Shares under the Act, or (iii) pursuant to an exemption
under Rule 144 under the Act or (iv) pursuant to another exemption from such

3

 

registration or in a transaction not subject to registration. For the purposes of this
section, “affiliate” means, with respect to any person, any entity controlling, controlled by or
under common control with such designated person, and “control” means the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract or otherwise.

     10. Registration Rights. The Holder is entitled to the benefit of certain
registration rights as set forth in the Stock Purchase Agreement (“Stock Purchase Agreement”), by
and between the holder and the Company, with respect to the shares of Common Stock issuable upon
the exercise of the Warrants evidenced by this Warrant Certificate. All registration rights under
the Stock Purchase Agreement shall expire and not apply to the Holder on the date the Holder is
eligible to sell pursuant to Rule 144 of the Act all Common Stock issuable upon the exercise of the
Warrants or the securities issued pursuant to the Stock Purchase Agreement.

     11. Fractional Shares. Notwithstanding that the number of Warrant Shares purchasable
upon the exercise of this Warrant Certificate may have been adjusted pursuant to the terms hereof,
the Company shall nonetheless not be required to issue fractions of shares upon the exercise of the
Warrants or to distribute certificates that evidence fractional shares nor shall the Company be
required to make any cash payments in lieu thereof upon exercise of the Warrants. Holder hereby
waives any right to receive fractional shares.

     12. Representations and Warranties of the Holder. The Holder represents and warrants
to the Company as follows:

          (a) Purchase for Own Account. This Warrant and the securities to be acquired upon
exercise of this Warrant by the Holder will be acquired for investment for the Holder’s account,
not as a nominee or agent, and not with a view to the public resale or distribution within the
meaning of the Act. Holder also represents that the Holder has not been formed for the specific
purpose of acquiring this Warrant or the Warrant Shares.

          (b) Investment Experience. The Holder understands that the purchase of this Warrant
and its underlying securities involves substantial risk. The Holder is an “Accredited Investor” as
defined in Regulation D of the Act and has experience as an investor in securities of companies
such as the Company and acknowledges that the Holder can bear the economic risk of such Holder’s
investment in this Warrant and its underlying securities and has such knowledge and experience in
financial or business matters that the Holder is capable of evaluating the merits and risks of its
investment in this Warrant and its underlying securities and/or has a preexisting personal or
business relationship with the Company and certain of its officers, directors or controlling
persons of a nature and duration that enables the Holder to be aware of the character, business
acumen and financial circumstances of such persons.

          (c) The Act. The Holder understands that neither this Warrant nor the Warrant Shares
have been registered under the Act in reliance upon a specific exemption therefrom, which exemption
depends upon, among other things, the bona fide nature of the Holder’s investment intent as
expressed herein.

     13. Successors and Assigns. This Warrant Certificate shall be binding on and inure to
the benefit of the heirs, executors, administrators, successors, and assigns of the respective
parties.

     14. Governing Law. This Warrant Certificate shall be governed by and construed in
accordance with the laws of the State of California, without regard to the conflicts of law
provisions of the State of California or of any other state.

4

 

     15. Amendment; Waiver. Any term of this Warrant Certificate may be amended or waived
upon mutual written consent of the Company and the Holder.

     16. Entire Agreement. This Warrant Certificate together with that certain Stock
Purchase Agreement constitutes the entire agreement between the parties hereto pertaining to the
subject matter hereof.

     IN
WITNESS WHEREOF, this Warrant Certificate has been executed as of this ___ day of
                    , 2008.

	 	 	 	 	 
	 	REMEDENT, INC.

a Nevada corporation

 	 
	 	By:  	 	 
	 	 	Name, Title 	 
	 	 	 	 

5

 

	 	 	 	 	 

EXHIBIT A

NOTICE OF EXERCISE

To Remedent, Inc.:

     The undersigned hereby irrevocably elects to exercise, pursuant to Section 2 of the Warrant
Certificate accompanying this Notice of Exercise, such number of Warrants to purchase shares of
Common Stock (the “Warrant Shares”) of Remedent, Inc., a Nevada corporation (the “Company”), in
accordance with the terms of the Warrant Certificate and herewith makes payment of the Purchase
Price of such Warrant Shares in full.

- OR -

     The undersigned hereby irrevocably elects to exercise pursuant to Section 2 of the Warrant
Certificate accompanying this Notice of Exercise, such number of Warrants to purchase 
shares of Common Stock (the “Warrant Shares”) of the Company pursuant to the net exercise
method resulting in the Warrant Shares.

	 	 	 	 	 	 	 	 	 	 	 
	Date:
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Name of Holder	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Signature	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Address:exv10w1

Exhibit 10.1

[***] Represents material which has been redacted and filed separately with the Commission pursuant
to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.

DISTRIBUTION, LICENSE AND

MANUFACTURING AGREEMENT

by and among

REMEDENT, INC.,

REMEDENT, N.V.,

and

DEN-MAT HOLDINGS, LLC

Dated as of August 24, 2008

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	1. DEFINED TERMS
	 	 	1	 
	 
	 	 	 	 
	2. DISTRIBUTION RIGHTS
	 	 	1	 
	 
	 	 	 	 
	2.1 Appointment as Distributor of the Products
	 	 	1	 
	 

	2.2 Future Increase of the Territory
	 	 	2	 
	 

	2.3 Potential Future Distribution Rights
	 	 	4	 
	 

	2.4 Cessation of Use
	 	 	7	 
	 
	 	 	 	 
	3. INTELLECTUAL PROPERTY LICENSE RIGHTS
	 	 	7	 
	 
	 	 	 	 
	3.1 Grants
	 	 	7	 
	 

	3.2 Rights in Future Intellectual Property
	 	 	8	 
	 

	3.3 Delivery of Intellectual Property
	 	 	9	 
	 

	3.4 Cessation of Use
	 	 	9	 
	 

	3.5 Ownership of Intellectual Property
	 	 	10	 
	 
	 	 	 	 
	4. MANUFACTURING RIGHTS
	 	 	11	 
	 
	 	 	 	 
	4.1 Products
	 	 	11	 
	 

	4.2 Termination of Right
	 	 	11	 
	 
	 	 	 	 
	 
	 	 	 	 
	5. MANUFACTURING RELATIONSHIP
	 	 	11	 
	 

	5.1 Soca
	 	 	11	 
	 

	5.2 Other Manufacturers
	 	 	11	 
	 
	 	 	 	 
	6. PAYMENTS
	 	 	12	 
	 
	 	 	 	 
	6.1 Fixed Payments
	 	 	12	 
	 

	6.2 Other Payments
	 	 	12	 
	 

	6.3 Manufacturing Payment During the Exclusivity Period
	 	 	13	 
	 

	6.4 Manufacturing Payment After the Guaranty Period
	 	 	13	 
	 

	6.5 Payment and Reports
	 	 	14	 
	 
	 	 	 	 
	7. GUARANTY PERIOD; PURCHASE RIGHTS AND OBLIGATIONS WITH RESPECT TO PRODUCTS MANUFACTURED BY REMEDENT
	 	 	14	 
	 
	 	 	 	 
	7.1 Purchases of Units/Teeth
	 	 	14	 
	 

	7.2 Purchases of Trays
	 	 	15	 
	 

	7.3 Off-Set
	 	 	15	 
	 

	7.4 Price Reductions
	 	 	16	 

 -i-

 

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	7.5 Option to Extend Guaranty Period
	 	 	16	 
	 
	 	 	 	 
	 

	8. ORDER FULFILLMENT, INVENTORY AND MANUFACTURING
	 	 	17	 
	 
	 	 	 	 

	 

	8.1 Order Process
	 	 	17	 

	 

	8.2 Changes to Orders
	 	 	18	 

	 

	8.3 Shipping; Title and Risk of Loss
	 	 	18	 

	 

	8.4 Invoicing and Payment
	 	 	18	 

	 

	8.5 Inventory
	 	 	18	 

	 

	8.6 Acceptance and Return of Products
	 	 	18	 

	 

	8.7 Production and Quality; Record
	 	 	19	 

	 

	8.8 Inspection and Oversight by Den-Mat
	 	 	19	 

	 

	8.9 Inspection and Oversight by Remedent
	 	 	19	 
	 
	 	 	 	 
	9. ENFORCEMENT OF RIGHTS
	 	 	19	 
	 
	 	 	 	 
	9.1 Distribution Agreements
	 	 	19	 

	 

	9.2 Intellectual Property
	 	 	20	 
	 
	 	 	 	 
	10. TRAINING AND SUPPORT; DELIVERY OF CUSTOMER INFORMATION
	 	 	21	 
	 
	 	 	 	 
	10.1 Manuals and Information
	 	 	21	 

	 

	10.2 Manufacturing
	 	 	21	 

	 

	10.3 Marketing and Sales Assistance
	 	 	21	 

	 

	10.4 Customer Information
	 	 	22	 

	 

	10.5 Executive Support
	 	 	22	 

	 

	10.6 Advertising
	 	 	22	 

	 

	10.7 Regulatory Matters
	 	 	23	 
	 
	 	 	 	 
	11. CHANGE OF CONTROL
	 	 	23	 
	 
	 	 	 	 
	11.1 Option to Receive Exit Fee
	 	 	23	 

	 

	11.2 Calculation of Exit Fee
	 	 	23	 

	 

	11.3 Effect of Payment of Exit Fee
	 	 	24	 
	 
	 	 	 	 
	12. PAYMENT TERMS, TAXES AND AUDITS
	 	 	25	 
	 
	 	 	 	 
	12.1 Payment
	 	 	25	 

	 

	12.2 Taxes
	 	 	25	 

	 

	12.3 Audit
	 	 	25	 

 -ii-

 

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	13. TERM AND TERMINATION
	 	 	26	 
	 
	 	 	 	 
	13.1 Term
	 	 	26	 

	 

	13.2 Termination for Cause
	 	 	26	 

	 

	13.3 Termination for Convenience
	 	 	27	 

	 

	13.4 Sell-Off Period
	 	 	27	 

	 

	13.5 Survival
	 	 	28	 
	 
	 	 	 	 
	14. REPRESENTATIONS AND WARRANTIES
	 	 	28	 
	 
	 	 	 	 
	14.1 Representations and Warranties of Remedent
	 	 	28	 

	 

	14.2 Representations and Warranties of Den-Mat
	 	 	33	 
	 
	 	 	 	 
	15. CLOSING
	 	 	35	 
	 
	 	 	 	 
	16. CLOSING CONDITIONS
	 	 	35	 
	 
	 	 	 	 
	16.1 Conditions to the Obligation of Remedent
	 	 	35	 

	 

	16.2 Conditions to the Obligation of Den-Mat
	 	 	35	 
	 
	 	 	 	 
	17. CONFIDENTIALITY
	 	 	36	 
	 
	 	 	 	 
	17.1 Confidential Information of Den-Mat
	 	 	36	 

	 

	17.2 Confidential Information of Remedent
	 	 	37	 
	 
	 	 	 	 
	18. INDEMNIFICATION
	 	 	38	 
	 
	 	 	 	 
	18.1 Indemnification by Den-Mat
	 	 	38	 

	 

	18.2 Indemnification by Remedent
	 	 	39	 

	 

	18.3 IP Indemnity
	 	 	39	 

	 

	18.4 Indemnification Procedures
	 	 	39	 
	 
	 	 	 	 
	19. FORCE MAJEURE EVENTS
	 	 	40	 
	 
	 	 	 	 
	19.1 No Liability
	 	 	40	 

	 

	19.2 Notification
	 	 	40	 

	 

	19.3 Termination
	 	 	40	 
	 
	 	 	 	 
	20. MISCELLANEOUS
	 	 	41	 
	 
	 	 	 	 
	20.1 Expenses
	 	 	41	 

	 

	20.2 Further Actions
	 	 	41	 

	 

	20.3 Notices
	 	 	41	 

	 

	20.4 Binding Effect; Assignment
	 	 	42	 

 -iii-

 

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	20.5 Amendment; Waiver
	 	 	42	 

	 

	20.6 Entire Agreement
	 	 	43	 

	 

	20.7 Severability
	 	 	43	 

	 

	20.8 Headings
	 	 	43	 

	 

	20.9 Counterparts
	 	 	43	 

	 

	20.10 Governing Law
	 	 	43	 

	 

	20.11 Consent to Jurisdiction
	 	 	43	 

	 

	20.12 Waiver of Punitive and Other Damages and Jury Trial
	 	 	44	 

	 

	20.13 No Waiver; Remedies
	 	 	45	 

	 

	20.14 No Limitation on Competitive Activities
	 	 	45	 

	 

	20.15 No Partnership or Joint Venture
	 	 	45	 

	 

	20.16 Jointly Drafted; Review by Counsel
	 	 	45	 

	 

	20.17 Specific Performance
	 	 	45	 

	 

	20.18 Interpretation
	 	 	45	 

	 

	20.19 Mitigation
	 	 	46	 

 -iv-

 

 

DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT

     THIS DISTRIBUTION, LICENSE AND MANUFACTURING AGREEMENT (this “Agreement”) is made as
of August 24, 2008 (the “Effective Date”) by and among Remedent, Inc., a Nevada corporation
(“Remedent Nevada”), Remedent N.V., a Belgian corporation (“Remedent Belgium”, and
together with Remedent Nevada, “Remedent”), and Den-Mat Holdings, LLC, a Delaware limited
liability company (“Den-Mat”).

     WHEREAS, Remedent has developed and desires to market, distribute, license and sell certain
products and services and Remedent desires to appoint Den-Mat to act as the sole and exclusive
distributor of such products and services for Remedent in the Territory (as defined below) and,
with certain limitations, as a non-exclusive distributor of such products and services for Remedent
outside the Territory;

     WHEREAS, Den-Mat and Remedent have agreed that Den-Mat will purchase certain products
manufactured by or for Remedent for a specified period of time (subject to extension) and that
Den-Mat will make royalty payments to Remedent in connection with the sale of certain products by
Den-Mat;

     WHEREAS, Remedent owns certain patents, trademarks and other intellectual property, and has
rights pursuant to certain licenses and other agreements with respect to other patents, trademarks
and other intellectual property, and Remedent desires to grant to Den-Mat (to the extent such third
party licenses and other agreements permit) an exclusive license of such patents, trademarks and
other intellectual property in the Territory and a non-exclusive license of such patents,
trademarks and other intellectual property in the Excluded Markets and the China Market (each as
defined below); and

     WHEREAS, Remedent desires to grant Den-Mat the non-exclusive right to manufacture or have
manufactured certain products developed by Remedent.

     NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Remedent and Den-Mat
hereby agree as follows.

1. Defined Terms.

     Capitalized terms used herein without definition shall have the respective meanings given to
them in Schedule 1.

2. Distribution Rights.

2.1 Appointment as Distributor of the Products.

     2.1.1 Exclusive Distributor. Subject to the terms and conditions in this Agreement,
Remedent hereby appoints Den-Mat as the sole and exclusive (even as to Remedent) distributor to
market, distribute, license and sell Products in the Territory, and Den-Mat hereby accepts this
appointment. For each market in the Territory, Den-Mat may appoint one or more sub-

 

 

distributors and subcontractors to market, distribute, license and sell the Products in the
Territory, without Remedent’s consent.

     2.1.2
Treatment of China. [***]

     2.1.3 Non-Exclusive Distributor. [***]

     2.1.4 Subdistributors. Den-Mat may authorize sub-distributors and subcontractors to
market, distribute, license and sell Products in accordance with this Section 2, provided
that within ten (10) days after the appointment of such sub-distributor or subcontractor after the
Effective Date, Den-Mat shall notify Remedent of the identity, address and market of such
sub-distributor or subcontractor. Den-Mat shall not sell or otherwise transfer Products to any
sub-distributor or subcontractor until such sub-distributor or subcontractor enters into a form of
written agreement (“Subdistributor Agreement”) with Den-Mat, which shall (a) include
provisions to bind such sub-distributor or subcontractor to terms and conditions substantially
similar to the product and territorial scope and other limitations set forth in Sections 2
and 3 and (b) authorize Remedent to enforce such provisions.

2.2 Future Increase of the Territory.

     2.2.1
Addition of Excluded Markets. [***] 

-2-

 

     2.2.2 Addition of China Market. [***] 

-3-

 

     2.2.3 Expansion of Territory. [***] 

2.3 Potential Future Distribution Rights.

     2.3.1 Right to Distribute Future Remedent Veneer Products. Remedent hereby grants
Den-Mat the first right to hold sole and exclusive distribution rights to market, distribute,
license and sell all future veneer products that are not GlamSmile Products (each, a “Remedent
Veneer Product”) developed (whether directly or indirectly, individually or jointly with
others) by or for Remedent (or any of Remedent’s Affiliates) in all existing and future markets
worldwide; provided, however, that any grant of rights developed jointly with
others will be subject to the rights, if any, of the joint developers. Remedent shall give Den-Mat
written notice of each additional Remedent Veneer Product as the same is developed, which notice
shall identify such Remedent Veneer Product and the anticipated market therefor. Remedent shall
not market, distribute, license or sell any Remedent Veneer Product except through a third party
pursuant to a written agreement, and Remedent shall not grant to any Person the right to
manufacture, market, license, distribute or sell any Remedent Veneer Product unless it has complied
with this Section 2.3.1. Prior to appointing any Person as a distributor for any Remedent
Veneer Product: Remedent shall deliver to Den-Mat (a) at least thirty (30) days prior to entering
into such distribution agreement, a notice identifying the Remedent Veneer

-4-

 

Product(s) that is the subject of such distribution agreement, the identity of the proposed
distributor and a summary of the terms and conditions of such proposed distribution agreement, and
(b) at least fifteen (15) days prior to entering into such distribution agreement, a copy of the
complete and final proposed distribution agreement and a notice of the date on which such
distribution agreement is to be executed (the “Proposed Remedent Veneer Signing Date”). At
any time prior to the second Business Day preceding the Proposed Remedent Veneer Signing Date set
forth in such notice from Remedent, Den-Mat may elect, effective upon delivery of notice to that
effect to Remedent, to enter into such distribution agreement in lieu of such other Person on the
terms and conditions set forth in such final distribution agreement (but with appropriate
modifications to the terms thereof to the extent any of the terms of such final distribution
agreement are unique to such other Person and are incapable of performance by Den-Mat). If Den-Mat
notifies Remedent that it elects to enter into such distribution agreement in lieu of such other
Person, Den-Mat and Remedent shall promptly thereafter negotiate in good faith any appropriate
modifications to the terms thereof, to the extent any of the terms of such final distribution
agreement are unique to such other Person and are incapable of performance by Den-Mat, and execute
and deliver such distribution agreement. If Den-Mat does not deliver a notice of exercise with
respect to any distribution agreement for Remedent Veneer Product(s) prior to the second Business
Day preceding the Proposed Remedent Veneer Signing Date, as referred to above, then during the ten
(10) Business Day period commencing with such Proposed Remedent Veneer Signing Date, Remedent and
such other Person may enter into the final distribution agreement, provided there is no
modification of the terms thereof from the final version provided to Den-Mat. If Remedent and such
Person do not enter into a distribution agreement within the ten (10) Business Day period referred
to in the preceding sentence, Remedent shall not thereafter enter into a distribution agreement
with respect to the Remedent Veneer Product(s) subject to such agreement (with such Person or any
other Person) without first again complying with each of the procedures set forth in this
Section 2.3.1.

     2.3.2 Right of First Offer on Other Remedent Potential Products. Remedent hereby
grants Den-Mat the right of first offer to have the sole and exclusive worldwide right to market,
distribute, license and sell all of the Other Potential Products (a) worldwide, or alternatively,
(b) in one or more of the United States, the United Kingdom and Canada. Remedent shall give
Den-Mat written notice of each Other Potential Product as the same is developed, which notice shall
identify such Other Potential Product and the anticipated market therefor. During the forty-five
(45) day period after delivery of such notice, Remedent shall provide such information and access
to its development, marketing and sales personnel as Den-Mat may reasonably request in order to
evaluate such Other Potential Product. On or before the expiration of such forty-five (45) day
period, Den-Mat shall notify Remedent if it elects to exercise the rights granted under this
Section 2.3.2, and if Den-Mat fails to notify Remedent during such forty-five (45) day
period it will be deemed to have waived its rights under this Section 2.3.2 with respect to
such Other Potential Product. If Den-Mat delivers such a notice, Den-Mat and Remedent shall
promptly commence negotiations with respect to the terms and conditions on which Den-Mat will
become the sole and exclusive distributor for such Other Potential Product on a worldwide basis or
in one or more of the United States, the United Kingdom and Canada, and Den-Mat and Remedent shall
engage in such negotiations in good faith. During the period commencing on the delivery of such
notice by Remedent and ending on the later of (a) the end of such forty-five (45) day period, or,
if earlier, the date Den-Mat notifies Remedent that it will not exercise its rights under this
Section 2.3.2 with respect to such Other

-5-

 

Potential Product or (b) the date negotiations between Den-Mat and Remedent with respect to a
potential distribution agreement with respect to such Other Potential Product terminate, Remedent
shall not directly distribute, nor shall it authorize any Person to distribute, such Other
Potential Product. If Remedent notifies Den-Mat of any Other Potential Product and Den-Mat does
not deliver to Remedent the notice of exercise referred to above or reach an agreement with
Remedent to become a distributor with respect to such Other Potential Product, or Den-Mat waives
the right of first offer under this Section 2.3.2, Remedent may thereafter market ,
distribute, license and sell such Other Potential Product, including the use of sub-distributors
and subcontractors, provided, however, Remedent shall not designate any licensee,
subcontractor or distributor for such Other Potential Product on a worldwide basis or in the United
States, the United Kingdom or Canada except as hereafter provided in this Section 2.3.2.

          (i) Appointment Within Six Months. If Remedent notifies Den-Mat of any Other
Potential Product and Den-Mat does not become the sole and exclusive distributor of such Other
Potential Product, either because Den-Mat does not exercise its rights under this Section
2.3.2 with respect to such Other Potential Product or, having exercised such rights, is unable
to reach agreement with Remedent with respect to the terms and conditions of such distribution
agreement, Remedent may designate another Person as the exclusive distributor of such Other
Potential Product worldwide or in one or more of the United States, the United Kingdom and Canada
at any time during the six (6) month period after the later of the expiration of the forty five
(45) day period referred to above or the date Remedent and Den-Mat terminate their negotiations
regarding the terms and conditions of such distribution agreement; provided,
however, if Den-Mat delivered a notice of exercise with respect to such Other Potential
Product during the forty five (45) day period referred to above, the terms and conditions of the
distribution agreement with such other Person shall not be more favorable to such other Person than
the terms and conditions last offered in writing by Remedent to Den-Mat. If Remedent has not
entered into an exclusive distribution agreement with respect to such Other Potential Product on a
worldwide basis or in the United States, the United Kingdom or Canada, as the case may be, within
the six (6) month period referred to in the preceding sentence, it may not thereafter appoint a
distributor for such Other Potential Product in such territory unless it again complies with the
procedures set forth above in this Section 2.3.2.

          (ii) Different Scope. If Remedent notifies Den-Mat of any Other Potential Product and
Den-Mat does not become the sole and exclusive distributor of such Other Potential Product
worldwide or in the United States, the United Kingdom or Canada (as applicable for purposes of this
Section 2.3.2(ii)), either because Den-Mat does not exercise its rights under this
Section 2.3.2 with respect to such Other Potential Product or, having exercised such
rights, is unable to reach agreement with Remedent with respect to the terms and conditions of such
distribution agreement, Remedent may from time to time designate another Person as a distributor of
such Other Potential Product in one or more markets less than all of the United States, the United
Kingdom or Canada or on a scope less than sole and exclusive in one or more of such markets if
Remedent: (A) delivers to Den-Mat at least thirty (30) days prior to entering into such
distribution agreement, a notice identifying the Other Potential Product that is the subject of
such distribution agreement, the identity of the proposed distributor and a summary of the terms
and conditions of such proposed distribution agreement, and (B) delivers to Den-Mat at least
fifteen (15) days prior to entering into such distribution agreement, a copy of the complete and
final proposed distribution agreement and a notice of the date on which such distribution

-6-

 

agreement is to be executed (the “Proposed Remedent Other Products Signing Date”). At
any time prior to the second Business Day preceding the Proposed Remedent Other Products Signing
Date set forth in such notice from Remedent, Den-Mat may elect, effective upon delivery of notice
to that effect to Remedent, to enter into such distribution agreement in lieu of such other Person
on the terms and conditions set forth in such final distribution agreement (but with appropriate
modifications to the terms thereof to the extent any of the terms of such final distribution
agreement are unique to such other Person and are incapable of performance by Den-Mat). If Den-Mat
notifies Remedent that it elects to enter into such distribution agreement in lieu of such other
Person, Den-Mat and Remedent shall promptly thereafter negotiate in good faith any appropriate
modifications to the terms thereof, to the extent any of the terms of such final distribution
agreement are unique to such other Person and are incapable of performance by Den-Mat, and execute
and deliver such distribution agreement. If Den-Mat does not deliver a notice of exercise with
respect to any distribution agreement for Other Potential Product(s) prior to the second Business
Day preceding the Proposed Remedent Other Products Signing Date, as referred to above, then during
the five (5) day period commencing with such Proposed Remedent Other Products Signing Date,
Remedent and such other Person may enter into the final distribution agreement, provided there is
no modification of the terms thereof from the final version provided to Den-Mat. If Remedent and
such Person do not enter into a distribution agreement within the five (5) day period referred to
in the preceding sentence, Remedent shall not thereafter enter into a distribution agreement with
respect to the Other Potential Product(s) subject to such agreement (with such Person or any other
Person) without first again complying with each of the procedures set forth in this Section
2.3.2(ii) (and if more than six (6) months have passed since Remedent last delivered the notice
contemplated by the second sentence of this Section 2.3.2, also comply with each of the
other provisions of this Section 2.3.2).

2.4 Cessation of Use.

     2.4.1 End of Guaranty Period. Upon expiration or termination of the Guaranty Period,
the sole and exclusive distribution rights provided for in Section 2.1.1 shall be amended,
without the need for any further action by any Party, to become non-exclusive distribution rights
instead of sole and exclusive distribution rights (with the effect that the phrase ‘the sole and
exclusive (even as to Remedent)’ in Section 2.1.1 shall be deemed to mean ‘non-exclusive’
even if the text is not physically modified).

     2.4.2 End of Agreement. Upon termination of this Agreement or, if later, upon the
conclusion of any applicable Sell-Off Period, Den-Mat shall cease having rights to market,
distribute, license and sell Products in the Territory.

3. Intellectual Property License Rights.

3.1 Grants.

     3.1.1 Use of Existing Intellectual Property in the Territory. Subject to the terms
and conditions in this Agreement, Remedent hereby grants to Den-Mat a sole and exclusive (even as
to Remedent) transferable and sublicensable right and license to use within the Territory the
Intellectual Property owned or used by Remedent that is related to the Products as it exists on the
Effective Date. Notwithstanding the foregoing, (a) Remedent retains the right to use and

-7-

 

license to any Person performing contract manufacturing for Remedent (concurrently with
Den-Mat’s right to use) such Intellectual Property solely in connection with the manufacture of the
Products and for internal product development related to the Products and (b) this grant shall not
include any rights to the name or trademark ‘Remedent’. For purposes of clarity, during the
Guaranty Period Remedent shall not use the name or trademark ‘GlamSmile’ in the Territory without
the prior written consent of Den-Mat. During the forty-five (45) day period after the Effective
Date, Den-Mat shall provide such cooperation to Remedent as Remedent may reasonably request related
to developing and implementing guidelines for use of the trademarks included among the Intellectual
Property licensed to Den-Mat pursuant to this Section 3.1.1 sufficient to enable Remedent
to preserve such trademarks; provided, however, Den-Mat shall not be required to
adopt or implement any such guideline to the extent doing so would adversely affect Den-Mat’s
ability to comply with the terms of this Agreement, materially impact Den-Mat’s costs of
performance under this Agreement or otherwise would not be commercially reasonable.

     3.1.2 Use of Existing Intellectual Property in the Excluded Markets. Subject to the
terms and conditions in this Agreement, Remedent hereby grants to Den-Mat a non-exclusive,
transferable and sublicensable right and license to use in the China Market and the Excluded
Markets the Intellectual Property licensed or owned by Remedent that is related to the Products,
whether existing on the Effective Date or developed or acquired by Remedent after the Effective
Date, except (a) as specifically identified on Schedule 3.1.2, (b) subject to the
limitations set forth in Section 3.2, (c) this grant shall not include any rights to the
name or trademark ‘Remedent’ and (d) use of the “GlamSmile” name or trademark in the Excluded
Markets shall be limited as provided in Schedule 3.1.2.

     3.1.3 Use of Future Intellectual Property. Subject to the terms and conditions in
this Agreement, Remedent hereby grants to Den-Mat a sole and exclusive (even as to Remedent)
transferable and sublicensable right and license to use within the Territory the Intellectual
Property owned or used by Remedent that is related to the Products and is developed (whether
directly or indirectly, individually or jointly with others) by Remedent (or any of Remedent’s
Affiliates) or acquired by Remedent (or any of Remedent’s Affiliates) after the Effective Date,
except that (a) such grant is subject to the limitations set forth in Section 3.2, (b)
Remedent retains the right to use and license to any Person providing contract manufacturing to
Remedent (concurrently with Den-Mat’s right to use) such Intellectual Property solely in connection
with the manufacture of the Products for Den-Mat and for internal product development related to
the Products for Den-Mat and (c) Remedent retains the right to use and license to any Person
providing contract manufacturing to Remedent (concurrently with Den-Mat’s right to use) any of such
Intellectual Property directly related to the Product manufacturing process or the Tray delivery
process solely in connection with the manufacture of the Products.

3.2 Rights in Future Intellectual Property.

     3.2.1 Remedent. Remedent shall promptly notify Den-Mat of any Intellectual Property
developed (whether directly or indirectly, individually or jointly with others) by Remedent (or any
of Remedent’s Affiliates) or acquired by Remedent (or any of Remedent’s Affiliates) after the
Effective Date related to the Products and concurrently therewith deliver such Intellectual
Property to Den-Mat as provided in Section 3.3. The grants provided in Section 

-8-

 

3.1 shall not apply to any Intellectual Property licensed by Remedent after the
Effective Date for which, despite commercially reasonable efforts, Remedent is not able to obtain a
sublicense or the right to grant a sublicense enabling Remedent to grant the license contemplated
by Section 3.1; provided, however, Remedent shall not thereafter use such
Intellectual Property in competition with the Products during the Guaranty Period, except in the
Excluded Markets and in the China Market or in connection with the purpose of manufacturing the
Products for Den-Mat under the terms of this Agreement. Upon being advised that any Intellectual
Property Remedent desires to license from another Person after the Effective Date would not be
available to Den-Mat as contemplated by Section 3.1, Remedent shall give prompt written
notice of such event to Den-Mat and thereafter will not license such Intellectual Property without
first cooperating with Den-Mat for a period of at least fifteen (15) Business Days, in such manner
as Den-Mat may reasonably request, to obtain a license of such Intellectual Property, on
commercially reasonable terms, in the scope contemplated by Section 3.1 or in such more
limited scope as Den-Mat may agree.

3.3 Delivery of Intellectual Property. In connection with the licenses granted to Den-Mat
pursuant to Section 3.1, Remedent shall deliver to Den-Mat, not less than one (1) copy of
all computer object code (in machine readable form) and all computer source code and other
technology related to the Intellectual Property of Remedent that is related to the Products;
provided, however, the source code related to the software licensed from SensAble
Technologies, Inc. shall not be delivered and instead shall be held in an escrow arrangement of
which Remedent shall cause Den-Mat to be a direct beneficiary in the event of Remedent’s
bankruptcy. From time to time as upgrades or updates of the source code are developed, Remedent
shall deliver to Den-Mat a copy of each such upgrade and update. Den-Mat will protect and maintain
the confidentiality of such source code and any confidential Intellectual Property provided to it
hereunder to the same extent as it protects and maintains the confidentiality of its own source
code and confidential Intellectual Property.

3.4 Cessation of Use.

     3.4.1 End of Guaranty Period. Upon expiration or termination of the Guaranty Period,
the sole and exclusive licenses provided in Section 3.1.1 shall be amended, without the
need for any further action by any Party, to become non-exclusive licenses instead of sole and
exclusive licenses (with the effect that the term ‘sole and exclusive’ in Section 3.1.1
shall be deemed to mean ‘non-exclusive’ even if the text is not physically modified). In addition,
upon expiration of the Guaranty Period, the right of Den-Mat to use any trademark of Remedent
included among the Intellectual Property of Remedent initially licensed under Section 3.1
shall immediately terminate, except in connection with Den-Mat’s sale, in the ordinary course of
business, of its remaining inventory of Products bearing such trademarks.

     3.4.2 End of Agreement. Upon termination of this Agreement or, if later, upon the
conclusion of any applicable Sell-Off Period, Den-Mat shall cease using all Intellectual Property
of Remedent and all materials, in any format or media, bearing or using the Intellectual Property
of Remedent, and promptly return or destroy all tangible and electronic copies of such Intellectual
Property, as requested by Remedent, and upon the request of Remedent, certify such destruction in
writing. Notwithstanding the foregoing provisions of this Section 3.4.2, Den-Mat may retain
one (1) copy of the Intellectual Property of Remedent for Den-Mat’s internal

-9-

 

compliance purposes, provided Den-Mat shall protect and maintain the confidentiality of the
Intellectual Property retained by it to the same extent as it protects and maintains the
confidentiality of its own Intellectual Property.

3.5 Ownership of Intellectual Property.

     3.5.1 Independently Developed Intellectual Property. Subject to Section
3.5.2, each Party shall have the sole and exclusive right to apply for, prosecute and obtain
all rights, grants, registrations, orders or proprietary interests of any nature, including,
without limitation, patents, copyrights, industrial design and trademark and service mark
registrations and any other registrations or grants of rights that are analogous thereto in any and
all countries throughout the world in respect of Intellectual Property now owned or independently
developed by such Party after the Effective Date. In addition, with respect to any Intellectual
Property related to the Products developed by Remedent (and not subject to Section 3.5.2),
Remedent, in its sole discretion at its own cost and expense may apply for, prosecute and obtain
all rights, grants, registrations, orders or proprietary interests of any nature, including,
without limitation, patents, copyrights, industrial design and trademark and service mark
registrations and any other registrations or grants of rights that are analogous thereto in any and
all countries throughout the world, in each case as reasonably requested by Den-Mat, and take such
other actions as Den-Mat may reasonably request to protect such Intellectual Property. In the
event Remedent fails to take any action reasonably requested by Den-Mat as described in the
preceding sentence: (a) Den-Mat may take such action, (b) Remedent hereby authorizes Den-Mat to
take any such action in its name, (c) Remedent shall provide such assistance as Den-Mat may
reasonably request in connection therewith, (d) Den-Mat shall be reimbursed for the costs and
expenses incurred by it in connection with such actions as a priority payment from any sale,
license fees, royalties, proceeds of infringement actions or other amounts received by Remedent or
Den-Mat with respect to such Intellectual Property in the territory covered by such rights, grants,
registration orders or proprietary interests, (e) Remedent shall be reimbursed for the costs and
expenses incurred by it in connection with providing cooperation to Den-Mat related to obtaining
such rights, grants, registration orders or proprietary interests as a second priority payment from
any sale, license fees, royalties, proceeds of infringement actions or other amounts received by
Remedent or Den-Mat with respect to such Intellectual Property in the territory covered by such
rights, grants, registration orders or proprietary interests, (f) each of Den-Mat and Remedent
shall take such actions as the other may reasonably request to implement the provisions of this
Section 3.5.1 with respect to any particular Intellectual Property and (g) the rights,
grants, registration orders or proprietary interests so obtained shall be jointly owned by Remedent
and Den-Mat.

     3.5.2 Jointly Arising Intellectual Property. In the event the Parties jointly develop
any Intellectual Property related to the Products for which a patent or copyright would be
available, and if either Remedent or Den-Mat desires to pursue a patent or copyright on such
Intellectual Property in any jurisdiction, then the Party who desires to pursue such patent or
copyright (in this capacity, the “Filing Party”), shall deliver a notice (a “Notice of
Intent to File”) to the other Party identifying the subject Intellectual Property, whether the
filing will be for a patent or copyright and the jurisdiction in which such filing will be made.
The Party receiving such Notice of Intent to File may then elect to participate in such filing, in
which case it shall cooperate with the Filing Party in connection with such filing and the
subsequent prosecution

-10-

 

thereof and share the related costs and expenses evenly with the Filing Party. If the Party
receiving such Notice of Intent to File does not deliver to the Filing Party a notice that it
elects to participate in such filing and prosecution within thirty (30) days after receiving such
Notice of Intent to File, the Filing Party may proceed with such filing and prosecution
individually. If a Filing Party proceeds with such a filing and prosecution individually: (a) the
other Party hereby authorizes the Filing Party to identify such Party as a co-owner of the subject
Intellectual Property and a co-holder of the rights filed for, (b) the other Party shall provide
such assistance as the Filing Party may reasonably request in connection therewith, (c) the Filing
Party shall be reimbursed for the costs and expenses incurred by it in connection with such filing
and prosecution as a priority payment from any sale, license fees, royalties, proceeds of
infringement actions or other amounts received by Remedent or Den-Mat with respect to such
Intellectual Property in the territory covered by such patent or copyright, (d) the Filing Party
shall be reimbursed for the costs and expenses incurred by it in connection with providing
cooperation as a second priority payment from any sale, license fees, royalties, proceeds of
infringement actions or other amounts received by Remedent or Den-Mat with respect to such
Intellectual Property in the territory covered by such patent or copyright, (e) each of Den-Mat and
Remedent shall take such actions as the other may reasonably request to implement the provisions of
this Section 3.5.2 with respect to such Intellectual Property and (f) the patents or
copyrights so obtained shall be jointly owned by Remedent and Den-Mat. In order to avoid future
misunderstandings, the Parties agree that any Intellectual Property related to upgrading the Tray
shall be deemed to be jointly developed Intellectual Property for all purposes.

4. Manufacturing Rights.

4.1 Products. Remedent hereby grants to Den-Mat the non-exclusive worldwide right to
manufacture and produce the Products or have the Products manufactured and produced for Den-Mat.

4.2 Termination of Right. Upon termination of this Agreement, Den-Mat shall cease having
the right to manufacture Products. For purposes of clarity, termination of the Guaranty Period
separate from the termination of this Agreement shall not affect the rights granted by Section
4.1.

5. Manufacturing Relationship.

5.1 Soca. [***]

5.2 Other Manufacturers. [***]

6. Payments.

6.1 Fixed Payments.

     6.1.1 Closing Date Payment. Subject to the terms and conditions of this Agreement
(including the satisfaction of the closing conditions described in Section 16), Den-Mat
shall make an initial non-refundable payment of Two Million Four Hundred Twenty Five Thousand
Dollars ($2,425,000) (the “Upfront Payment”) to Remedent within two (2) Business Days after
the Closing Date.

-11-

 

     6.1.2 Contract Period Payments. Den-Mat shall make a payment of Two Hundred Fifty
Thousand Dollars ($250,000) with respect to each of the first three Contract Periods, which, with
respect to each such Contract Period, shall be due and payable upon the scheduled expiration of
such Contract Period. If the Guaranty Period is terminated prior to the end of any such Contract
Period pursuant to Section 13.2.2, no payment shall be made pursuant to this Section
6.1.2 with respect to such Contract Period. If the Guaranty Period is terminated prior to the
end of any such Contract Period, Den-Mat shall pay to Remedent within thirty (30) days after such
termination an additional [***] for each Tray sold in the Contract Period in which the Guaranty
Period was terminated, not to exceed Two Hundred Fifty Thousand Dollars ($250,000).

     6.1.3 Periodic Payments. As additional paid-up royalties in consideration of the
exclusive rights granted to Den-Mat under Sections 2 and 3, Den-Mat shall make
payments in the aggregate amount of Five Hundred Thousand Dollars ($500,000) to Remedent at the
times and in the amounts provided in Schedule 6.1.3; provided, however,
Den-Mat’s obligation to make each such payment shall be conditioned upon prior delivery to Den-Mat
of evidence, reasonably satisfactory to Den-Mat, that Remedent is in compliance with its
obligations under Section 10.3.3 at the time of such payment or will be in such compliance
simultaneously with the making of any such payment.

6.2 Other Payments.

     6.2.1 First Sale of Tray. Den-Mat shall make a payment of One Million Dollars
($1,000,000) to Remedent promptly after Den-Mat manufactures a case of Units/Teeth using the Tray
system in a Tray manufactured using the GlamSmile Technology and Processes at a facility owned or
leased by Den-Mat (a “Den-Mat Facility”) which is deemed by Den-Mat working together in
good faith with Remedent to be saleable to a customer. Den-Mat shall notify Remedent of the
satisfaction of the condition to the payment under this Section 6.2.1 promptly after
becoming aware of the satisfaction of such condition.

     6.2.2 Completion of Training. Den-Mat shall make a payment of One Million Dollars
($1,000,000) to Remedent promptly after completion of training regarding the manufacturing
equipment, as described on Schedule 10.2.

     6.2.3 Sale of Units/Teeth. Den-Mat shall make a payment of One Million Dollars
($1,000,000) to Remedent upon the first to occur of (a) February 1, 2009 or (b) the date thirty
(30) days after Den-Mat sells GlamSmile Products incorporating [***] Units/Teeth to customers
regardless of whether direct sales of Units/Teeth are sold in Trays and regardless of whether
Den-Mat has manufactured such Units/Teeth in a Den-Mat Facility or has purchased such Units/Teeth
from Remedent; provided, however, that if such payment date would be on or before
January 1, 2009, Den-Mat shall make the milestone payment described in this Section 6.2.3
on January 1, 2009. Den-Mat shall notify Remedent of the satisfaction of the condition to the
payment under this Section 6.2.3 promptly after becoming aware of the satisfaction of such
condition.

-12-

 

6.3 Manufacturing Payment During the Exclusivity Period.

     6.3.1 Royalty for Products Manufactured Using Tray Technology. Except as otherwise
set forth in Section 7, for each sale during the Exclusivity Period by Den-Mat of Products
manufactured by Den-Mat using the GlamSmile Tray Technology, Den-Mat shall pay to Remedent a
royalty payment equal to [***] of Den-Mat’s Net Wholesale Price per Unit/Tooth used in the Tray for
such sales; provided, however, (a) Den-Mat’s obligations to pay such royalties
shall apply only to sales after Den-Mat sells the first Tray manufactured in a Den-Mat Facility and
(b) if the aggregate payments of [***] are paid by Den-Mat pursuant to Sections 6.2.1 and
6.2.2, no royalty will be payable with respect to sales of the first [***] Teeth/Units
manufactured by Den-Mat.

     6.3.2 Royalty for Products Manufactured Using Non-Tray Technology. Except as
otherwise set forth in Section 7, for each sale during the Exclusivity Period by Den-Mat of
Products manufactured by Den-Mat using the GlamSmile Non-Tray Technology (and not covered by
Section 6.3.1), Den-Mat shall pay to Remedent a royalty payment equal to [***] of Den-Mat’s
Net Wholesale Price per Unit/Tooth used in such Product or, if such Product is a Unit/Tooth, [***] of Den-Mat’s Net Wholesale Price per Unit/Tooth.

6.4 Manufacturing Payment After the Guaranty Period.

     6.4.1 Royalty for Products Manufactured Using Tray Technology. For each sale after
the Guaranty Period by Den-Mat of Products manufactured by Den-Mat using the GlamSmile Tray
Technology, Den-Mat shall pay to Remedent a royalty payment equal to [***] of Den-Mat’s Net
Wholesale Price per Unit/Tooth used in the Tray for such sale.

     6.4.2 Royalty Payments for Products Manufactured Using Non-Tray Technology. Except as
otherwise set forth in Section 7, for each sale after the Guaranty Period by Den-Mat of
Products manufactured by Den-Mat using the GlamSmile Non-Tray Technology (and not covered by
Section 6.4.1), Den-Mat shall pay to Remedent a royalty payment equal to [***] of Den-Mat’s
Net Wholesale Price per Unit/Tooth used in such Product or, if such Product is a Unit/Tooth, [***]
of Den-Mat’s Net Wholesale Price per Unit/Tooth.

6.5 Payment and Reports. For purposes of Sections 6.3 and 6.4, a sale
shall be deemed to have been made by Den-Mat at the time the related revenue is recognized by
Den-Mat for its internal accounting purposes (in accordance with GAAP). Within sixty (60) days
after the end of each calendar quarter, Den-Mat shall deliver to Remedent a certified statement
from an officer of Den-Mat setting forth (a) the total amount of Den-Mat sales of Products
manufactured using the GlamSmile Tray Technology during such quarter, (b) the total amount of
Den-Mat sales of Products manufactured using the GlamSmile Non-Tray Technology during such quarter,
(c) only for the calendar quarters in which the Guaranty Period commences and terminates, the
amount of sales in such calendar quarter that were made during the Guaranty Period and the amount
of sales in such calendar quarter that were made before or after the Guaranty Period, as
applicable, (d) a calculation of the royalty offset, if any, pursuant to Section 6.3.1, (e)
a calculation of the royalties payable to Remedent under Sections 6.3 and 6.4 and
(f) the amount of such royalties attributable to sales in each of the United States, the United
Kingdom and Canada. Concurrently

-13-

 

with delivering such statement Den-Mat shall pay to Remedent the amount of the royalty payment set
forth on such statement.

7. Guaranty Period; Purchase Rights and Obligations With Respect to Products Manufactured by
Remedent.

7.1 Purchases of Units/Teeth.

     7.1.1 Minimum Purchases. Den-Mat shall have the obligation to purchase [***]
Units/Teeth from Remedent, without a Tray delivery system (subject to reductions in accordance with
Section 7.3), during each Contract Year; provided, however, if the final
Contract Year terminates prior to its scheduled termination date other than as a result of a
termination pursuant to Section 13.2.1, such obligation shall be prorated in such final
Contract Year based on the number of days in such Contract Year divided by 365. Den-Mat shall have
the right (but not the obligation) to purchase Units/Teeth from Remedent prior to the commencement
of the Guaranty Period.

     7.1.2 Additional Right to Purchase. Den-Mat shall have the right (but not the
obligation) to purchase up to [***] from Remedent, without a Tray delivery system, during each
Contract Year (for clarity, this is after the [***] Units/Teeth have been purchased in such
Contract Year pursuant to Section 7.1.1); provided, however, if the final
Contract Year terminates prior to its scheduled termination date other than as a result of
termination pursuant to Section 13.2.1, such obligation shall be prorated in such final
Contract Year based on the number of days in such Contract Year divided by 365.

     7.1.3 Additional Purchases. Den-Mat may purchase Units/Teeth from Remedent, without a
Tray delivery system, in excess of the amounts referred to in Sections 7.1.1 and
7.1.2 in any Contract Year if mutually agreed by Remedent and Den-Mat.

     7.1.4 Pricing. Any purchase by Den-Mat of Units/Teeth from Remedent pursuant to
Sections 7.1.1 and 7.1.2 shall be at a price of [***] per Unit/Tooth. Any purchase
by Den-Mat of Units/Teeth from Remedent pursuant to Section 7.1.3 shall be at a price
mutually agreed upon by Remedent and Den-Mat prior to the time of such sale. The prices referred
to in this Section 7.1.4 shall be subject to adjustment pursuant to Section 7.4 and
there shall be no royalty obligation on the sale thereof by Den-Mat (unless agreed upon by Remedent
and Den-Mat as part of the price under Section 7.1.3).

7.2 Purchases of Trays.

     7.2.1 Minimum Purchases. Den-Mat shall have the obligation to purchase [***] Trays
manufactured using the GlamSmile Tray Technology from Remedent (subject to reduction as provided in
Section 7.3.2) during each of the first three Contract Periods; provided,
however, if the final Contract Period terminates prior to its scheduled termination date
other than as a result of a termination pursuant to Section 13.2.1, then such obligation
shall be prorated based on the number of days in such Contract Period prior to such termination
divided by the number of days that would be in such Contract Period if such Contract Period had not
terminated prior to its scheduled termination.

-14-

 

     7.2.2 Additional Purchases. Den-Mat shall have the right (but not the obligation) to
purchase additional Trays manufactured using the GlamSmile Tray Technology from Remedent prior to
the commencement of the Guaranty Period and, during the Guaranty Period, in excess of the minimum
purchase requirements set forth in Section 7.2.1, in each case as mutually agreed by
Remedent and Den-Mat.

     7.2.3 Pricing. Any purchase by Den-Mat of Trays from Remedent pursuant to this
Section 7.2 shall be at the following price per Tray (subject to adjustment in accordance
with Section 7.4): (a) for each of the first [***] Trays in each of the first three
Contract Periods, [***] per Unit/Tooth in the Tray (which includes the digital design fee, the
digital preview file, the delivery/placement tray, any necessary reshaping or occlusal trays and
remakes); and (b) for each Tray after the [***] Trays in each of the first three Contract Periods,
such price as the Parties may agree. The prices referred to in this Section 7.2.3 shall be
subject to adjustment pursuant to Section 7.4 and there shall be no royalty obligation on
the sale by Den-Mat of the Trays referred to in the preceding clause (a), or, unless
mutually agreed upon by Den-Mat and Remedent, the preceding clause (b).

7.3 Off-Set.

     7.3.1 Teeth in Excess Trays. If Den-Mat purchases in excess of [***] Trays during any
Contract Year, the minimum purchase requirement of [***] Units/Teeth in such Contract Year (as
described in Section 7.1.1) shall be offset by the total amount of Units/Teeth that are
purchased in the excess Trays.

     7.3.2 Manufacturing Delay or Defect. Any Units/Teeth or Trays that are not delivered
within the periods required by Section 8.1 or which are Non-Conforming Products shall be
counted against the minimum purchase requirements set forth in Section 7.1.1 and
Section 7.2.1, but shall not count against the number of Units/Teeth Den-Mat may purchase
pursuant to Section 7.1.2 (in each case regardless of whether they are accepted by
Den-Mat).

7.4 Price Reductions.

     7.4.1 [***]

     7.4.2 Digital Design. Den-Mat shall have the right to perform the digital design
function at a Den-Mat Facility and, if Den-Mat provides such function with respect to any order,
there shall be credited against the cost of the related Product in such order an amount equal to
[***].

     7.4.3 Manufacturing Delay or Defect. With respect to any Products that are not
delivered within the periods required by Section 8.1 or which are Non-Conforming Products,
but which are nonetheless accepted by Den-Mat, the purchase price payable for such Product shall be
discounted by an amount equal to [***] of the full price for such Product from Remedent (for
purposes of clarity, before giving effect to any discount contemplated by Section 7.4.1,
Section 7.4.2 or otherwise).

-15-

 

7.5 Option to Extend Guaranty Period.

     7.5.1 Extension of Guaranty Period. Provided that Den-Mat satisfies its obligations
under Sections 7.1.1 and 7.2.1 for all periods ending on or before the third
(3rd) anniversary of the commencement of the Guaranty Period, the Guaranty Period shall
continue after the initial three (3) year term with such annual price adjustments as may be agreed
upon by Remedent and Den-Mat effective after such initial three (3) year term, unless the Guaranty
Period is terminated by Den-Mat in its sole discretion upon at least nine (9) months prior written
notice of termination to Remedent. Den-Mat may give such notice at any time, but if such notice is
given more than nine (9) months prior to the third (3rd) anniversary of the commencement
of the Guaranty Period, such termination shall not be effective until the third anniversary of the
commencement of the Guaranty Period. No later than ninety (90) days prior to the end of each
Contract Year (commencing in the third Contract Year and continuing thereafter unless the Guaranty
Period is scheduled to expire on or before the commencement of the next Contract Year), Remedent
shall provide to Den-Mat its proposed pricing for the subsequent Contract Year. If such proposed
price adjustment is not acceptable to Den-Mat, Remedent and Den-Mat will negotiate in good faith to
try to reach agreement on an appropriate price adjustment for the following Contract Year. If
Den-Mat and Remedent are unable to agree upon a price adjustment prior to the commencement of the
subsequent Contract Year, then Den-Mat shall be deemed to have accepted the best price proposal (to
Den-Mat) submitted in writing by Remedent, and such pricing proposal shall be the pricing of the
Products for such subsequent Contract Year, unless Den-Mat delivers to Remedent a notice of
termination on or before the tenth (10th) Business Day of such subsequent Contract Year.
If Den-Mat delivers such a notice of termination to Remedent on or before such date, then the
greater of (a) the prices in effect in the Contract Year in which Remedent first notified Den-Mat
of the proposed prices for such subsequent Contract Year or (b) the higher of (i) the best price
proposal (to Den-Mat) submitted in writing by Remedent or (ii) the prices described in Section
7 (without reference to the time period referred to therein) shall remain in effect until the
end of the Guaranty Period. The purchase requirements in Section 7 shall remain in effect
during any extension of the Guaranty Period or during the period referred to in the preceding
sentence, in each case unless mutually agreed by Den-Mat and Remedent or as expressly contemplated
by Section 13.2 or 19.3.

     7.5.2 Non-Extension of Guaranty Period. If the Guaranty Period expires pursuant to
Section 7.5.1, the licenses granted pursuant to Sections 2.1.1 and 3.1.1
shall be amended as provided in Sections 2.4.1 and 3.4.1; provided,
however, that Den-Mat shall not have the right to use any of Remedent’s trademarks,
including the “GlamSmile” name or brand after the expiration of the Guaranty Period;
provided, however, Den-Mat shall be permitted to use such trademarks in connection
with the sale of existing Products or Products ordered from Remedent and not delivered at the time
such right terminates, in each case in the ordinary course of distributing and selling such
Products. From and after the end of the Guaranty Period, prices for the Products Den-Mat may
purchase from Remedent shall be as Remedent and Den-Mat mutually agree; provided,
however, such prices shall be no less favorable to Den-Mat than the best price made
available by Remedent to any other Person after giving effect to Remedent’s published schedule of
volume discounts, if any.

-16-

 

8. Order Fulfillment, Inventory and Manufacturing.

8.1 Order Process. For each purchase of Products by Den-Mat from Remedent, Den-Mat shall
deliver to Remedent a purchase order in a form to be agreed upon by Remedent and Den-Mat,
specifying quantities and a shipping address for the Products to be purchased. For each Product,
Remedent shall have the time period specified in Schedule 8.1 to fulfill the order, which
shall be deemed fulfilled as of receipt by Den-Mat or at the other shipping address specified in
such order. Remedent shall not have the right to reject any order by Den-Mat that is for Products
Den-Mat is obligated or entitled to purchase pursuant to Sections 7.1.1, 7.1.2,
7.2.1 and 7.2.2. Remedent shall fulfill or cause its subcontractors and
manufacturers to fulfill all orders by Den-Mat in connection with Den-Mat’s minimum purchase
requirements and purchase rights, as described in Sections 7.1.1, 7.1.2,
7.2.1 and 7.2.2. If Remedent is unable to fulfill the orders for Products by
Den-Mat to satisfy Den-Mat’s minimum purchase requirements and purchase rights, as described in
Sections 7.1.1, 7.1.2, 7.2.1 and 7.2.2, within the maximum time
periods set forth on Schedule 8.1, Den-Mat may, in its sole discretion, refuse to accept
such Product or accept such Product with the price discount referred to in Section 7.4.3.
If Remedent is unable to fulfill the orders for Products by Den-Mat to satisfy Den-Mat’s minimum
purchase requirements and purchase rights, as described in Sections 7.1.1, 7.1.2,
7.2.1 and 7.2.2, Den-Mat shall have the right to find an alternative supply of such
Products (or manufacture such Products at a Den-Mat Facility), in which case Remedent shall pay to
Den-Mat any cost incurred by Den-Mat as a result of obtaining such Products from an alternative
supply or manufacturing such Products directly in excess of the purchase price provided in this
Agreement (inclusive of any discounts and set-offs available on the purchase price for such
Products provided in this Agreement) and the amount of Products so acquired or manufactured by
Den-Mat shall be counted towards any minimum purchase amounts under Section 7.1.1 and
7.2.1, as applicable. Such right shall be in addition to, and not as an alternative to,
any other rights of Den-Mat arising from a breach of this Agreement by Remedent. Remedent shall
have the right to reject orders by Den-Mat that are for products in excess of Den-Mat’s minimum
purchase requirements or purchase rights, as described in Sections 7.1.1, 7.1.2,
7.2.1 and 7.2.2.

8.2 Changes to Orders. Den-Mat may modify or cancel any order by delivering to Remedent a
notice describing such modification or cancellation. In such event, in lieu of the purchase price
for the Products subject to such order Den-Mat shall pay to Remedent: (a) with respect to a
cancelled order, the cost incurred by Remedent in connection with such order prior to delivery of
the notice of cancellation (but not more than the price for such Product under Section 7)
and (b) with respect to a modified order, the purchase price for the modified Product plus the
additional cost, if any, incurred by Remedent in connection with the completion of such order as so
modified.

8.3 Shipping; Title and Risk of Loss. All Products subject to each order shall be
delivered to Den-Mat or the Person designated as the recipient in such order at the shipping
address specified in such order, F.O.B. Remedent’s warehouse or manufacturing facility from which
such Products are shipped. Remedent will be responsible for arranging all transportation of
Products and shall insure all Products in a commercially reasonable manner. Title to, and risk of
loss of, the Products will pass to Den-Mat upon receipt of the Product by Den-Mat or the Person at
the shipping address designated in the related order. Remedent shall be responsible for all

-17-

 

freight, insurance, and shipping costs and duties, except Den-Mat shall be responsible for customs
duties.

8.4 Invoicing and Payment. Upon delivery and acceptance of Products, Remedent may submit
to Den-Mat an invoice for those Products consistent with Sections 7, 8 and the
other provisions of this Agreement. Den-Mat shall pay each proper invoice within [***] after
Den-Mat’s receipt of such invoice.

8.5 Inventory. Remedent shall be responsible for maintaining sufficient inventory of the
Products and raw materials to fulfill Den-Mat’s orders for the minimum purchase requirements or
Den-Mat’s purchase rights, as described in Sections 7.1.1, 7.1.2, 7.2.1 and
7.2.2. If Den-Mat provides Remedent a written forecast of orders that Den-Mat expects to
place with Remedent (for Products in excess of Den-Mat’s minimum purchase requirements and purchase
rights), Remedent shall use commercially reasonable efforts to maintain sufficient inventory of
Products to fulfill such orders for Den-Mat. Remedent shall bear all costs and losses associated
with the inventory of any Products, including inventory shrink, obsolescence, aged inventory,
damage, and Products not sold to Den-Mat or another Person.

8.6 Acceptance and Return of Products. Den-Mat shall, within a reasonable time after the
receipt of each shipment of Products and receipt of all necessary documentation associated with
each shipment (but in no event later than seven (7) days after receipt of such shipment), inspect
the Products and, after such inspection, (a) accept the shipment as a whole (as to quantity and
obvious damage of Products only), (b) reject the shipment as a whole or (c) reject the
Non-Conforming Products and accept the rest; provided, however, that any acceptance
by Den-Mat in accordance with clause (a) or clause (c) shall not preclude any
warranty claims by Den-Mat. In rejecting any shipments either in whole or in part, Den-Mat shall
notify Remedent in writing of the reason for the rejection and, at Remedent’s expense (including
costs of shipment) return the Non-Conforming Products to Remedent for confirmation of the defect.
With respect to any Non-Conforming Products, Den-Mat may, at its option, (i) return such
Non-Conforming Product to Remedent at Remedent’s expense (including costs of shipment) for repair
or replacement (at Remedent’s expense) or (ii) cancel the order and manufacture a replacement
Product. If Den-Mat elects to manufacture a replacement Product, it shall credit against any
amounts otherwise payable under this Agreement an amount equal to the price of such Product (and
without having any obligation to pay Remedent for the Non-Conforming Product).

8.7 Production and Quality; Record. All Products manufactured, sold and delivered to
Den-Mat by Remedent under this Agreement shall conform to the manufacturing standards and quality
requirements described on Schedule 8.7. Remedent shall maintain all Product quality
records in accordance with applicable laws and regulatory requirements, including those related to
medical devices, as applicable, related to the manufacture of the Products, and will make such
records available to Den-Mat upon reasonable advance request for review and audit. As soon as
practical after the date of this Agreement, Remedent shall obtain, and shall thereafter maintain,
the certifications set forth on Schedule 8.7, and shall provide such evidence of such
certifications as Den-Mat may from time to time reasonably request.

8.8 Inspection and Oversight by Den-Mat. At any time and from time to time, Den-Mat shall
have the right to send one or more of its authorized representatives to inspect, during

-18-

 

regular business hours, the manufacturing and warehouse facilities of Remedent used to manufacture,
package and store Products. Upon the request of Den-Mat, employees of Den-Mat shall be provided
with access to the facility in [***] operated by Soca Networks Pte. Ltd., and at each other
facility of Remedent as Den-Mat may from time to time request, to facilitate quality control and
inspection of Products prior to shipment, and Remedent will provide such employees with office
space, furniture and communications / computer facilities sufficient for them to achieve such
purposes, at Den-Mat’s sole cost and expense. As reasonably as practical after the commencement of
the Guaranty Period, Den-Mat shall commence quality control inspections in the [***] facility.

8.9 Inspection and Oversight by Remedent. At any time and from time to time, Remedent
shall have the right to send one or more of its authorized representatives to inspect, during
regular business hours, the manufacturing and warehouse facilities of Den-Mat used to manufacture,
package and store Products.

9. Enforcement of Rights.

9.1 Distribution Agreements. From and after the Effective Date, Remedent shall use its
best efforts to enforce each distribution agreement related to any of the Products in the Excluded
Markets and in the China Market to the fullest extent provided therein, except in each case, with
the prior written consent of Den-Mat. Without limitation to the preceding sentence, Remedent shall
not agree to or acquiesce in any amendment, waiver or forbearance of any provision of any such
distribution agreement, grant any extension of any such distribution agreement or fail to enforce
any right of termination arising from a breach thereof, without, in each case, the prior written
consent of Den-Mat. During the Exclusivity Period, without the prior written consent of Den-Mat,
Remedent shall not enter into any new distribution agreements, whether with an existing distributor
or a new distributor, with respect to any of the Products or which would preclude the sale of
Products by Den-Mat.

9.2 Intellectual Property.

     9.2.1 From and after the date of this Agreement, Remedent, at its sole discretion, in addition
to its obligations under Section 3.5.1, shall maintain all of its Intellectual Property
related to the Products and enforce all of its rights to protect against any infringing or
unauthorized use of such Intellectual Property by any Person, except in each case, with the prior
written consent of Den-Mat. Without limitation to the preceding sentence, (a) Remedent shall, at
its sole discretion, pay all renewal and maintenance fees on their trademarks, patents and other
Intellectual Property related to the Products, (b) Remedent shall not acquiesce in any infringement
by any Person of such Intellectual Property, nor shall it waive or forbear the exercise of its
rights with respect to any such infringement, without, in each case, the prior written consent of
Den-Mat and (c) Remedent shall not agree to or acquiesce in any amendment, waiver or forbearance of
any provision of any license or other grant by it of any interest in any such Intellectual Property
or fail to enforce any right of termination arising from a breach thereof, without, in each case,
obtaining the prior written consent of Den-Mat. In the event Remedent fails to take any such
action reasonably requested by Den-Mat referred to in this Section 9.2.1, Den-Mat may take
such action, and Remedent hereby authorizes Den-Mat to take any such action in its name. If
Remedent requests the assistance of Den-Mat in connection with

-19-

 

the taking of any actions by Remedent under this Section 9.2.1, then Den-Mat shall be
entitled to recoup its fees and expenses related thereto either from any recovery obtained by
Remedent (after Remedent has recouped its own costs and expenses related thereto) or by off-set
against its payment obligations to Remedent under this Agreement. In addition, if Den-Mat
commences an action in accordance with this Section 9.2.1 involving the commencement or
threatened commencement of an action involving an infringement of the Intellectual Property of
Remedent related to the Products, and Den-Mat is successful on such claims, then the amount payable
by the infringing party shall be applied: first, to pay any fees and expenses incurred by Den-Mat
in connection with such action, next to pay any fees and expenses incurred by Remedent in
connection with such action at the request of Den-Mat and, finally, [***].

     9.2.2 Remedent agrees that, during the Guaranty Period, in no case, under bankruptcy or
otherwise, shall it assign or license any of the Intellectual Property related to the Products or
dispose of any interest therein to a Person who is a direct competitor of Den-Mat or to any
successor or assign of any such Person; provided, however, Remedent may license
such Intellectual Property to any distributor of the Products as of the Effective Date for use in
the Excluded Markets and the China Market if such license does not breach any other provision of
this Agreement.

     9.2.3 Remedent acknowledges that this Agreement is an executory contract that would be subject
to the provisions of section 365(n) of the U.S. Bankruptcy Code if in the future an involuntary or
voluntary proceeding shall have been instituted in a court having jurisdiction seeking a decree or
order for relief in respect of Remedent under any applicable bankruptcy, insolvency or other
similar law now or hereafter in effect, or for the appointment of a receiver, liquidator, assignee,
custodian, trustee, sequestrator (or similar official) of Remedent or for any substantial part of
its property, or for the winding-up or liquidation of its affairs, and further acknowledges that
failure to perform continuing obligations under this Agreement would constitute material breach of
this Agreement. Remedent believes that the royalty payments set forth in this Agreement are
distinct from and separate from payments made in this Agreement for other services. Remedent
agrees that Den-Mat may assume or retain the licenses granted under this Agreement if any such
proceeding has been instituted, regardless of whether the underlying license is interpreted to
prohibit or restrict assignment in any manner, provided that Den-Mat continues to timely make the
royalty payments under this Agreement.

10. Training and Support; Delivery of Customer Information.

10.1 Manuals and Information. As promptly as practical after execution and delivery of
this Agreement, Remedent shall deliver to Den-Mat information, materials, manuals and other
technical documents of Remedent sufficient to enable Den-Mat to manufacture, market, distribute,
license and sell Products contemplated by this Agreement.

10.2 Manufacturing. Remedent shall dedicate sufficient resources, at its own expense, to
train Den-Mat and its employees in connection with GlamSmile Technology and Processes, the
manufacturing of Products and the establishment of manufacturing facilities for the Products.
Schedule 10.2 sets forth the time and scope of the services to be provided by Remedent. Any
training with respect to manufacturing beyond the term and scope set forth in Schedule 10.2
(or, for the avoidance of doubt, Schedule 10.3) shall be at Den-Mat’s expense.

-20-

 

10.3 Marketing and Sales Assistance.

     10.3.1 If Remedent is contacted by any Person seeking to acquire Products in the Territory,
Remedent shall refer such sales lead promptly to Den-Mat.

     10.3.2 In addition, Remedent shall provide such commercial and technical assistance to
Den-Mat, as Den-Mat may reasonably request in connection with the marketing, distribution and sale
by Den-Mat of Products under this Agreement. Remedent shall train the appropriate employees of
Den-Mat in marketing the Products. At least one (1) time during each calendar year during the
Guaranty Period, qualified employees of Remedent shall meet with representatives of Den-Mat, at
Remedent’s expense and at such location as Den-Mat may designate, to assist in technical training,
sales and/or important customer meetings. In addition, Remedent shall use all commercially
reasonable efforts to cause the individuals specified on Schedule 10.3.2 to provide sales
and marketing training, education of Den-Mat’s sales and marketing force and customers and other
services related to sales and marketing as Den-Mat may reasonably request from the Effective Date
through at least January 1, 2009, at no cost or expense to Den-Mat. If any of such persons ceases
to be an employee of or consultant to Glamtech-USA, Inc. or Remedent during such period, Remedent
shall use its commercially reasonable efforts to cause a replacement for such individual, as
Remedent and Den-Mat may agree, to provide such services to Den-Mat. Any training and support with
respect to marketing and sales assistance and training beyond the scope set forth in this
Section 10.3.2 (or, for the avoidance of doubt, Section 10.2) shall be at Den-Mat’s
expense.

     10.3.3 Remedent shall develop and implement a marketing program with respect to the Products
and the commencement of Den-Mat’s distribution of the Products in the Territory, which program
shall be subject to the prior approval of Den-Mat, such consent not to be unreasonably withheld.
Such marketing program shall be consistent with, and Remedent shall make all payments as and when
due in accordance with, the budget and timeline set forth in Schedule 10.3.3, subject to
such modifications as Remedent and Den-Mat may mutually agree. No provision of this Section
10.3.3 shall require Remedent to make expenditures in excess of [***] with respect to the
marketing program for Products and the commencement of Den-Mat’s distribution of the Products in
the Territory. Remedent shall consult with Den-Mat and give due consideration to Den-Mat’s views
regarding such marketing program from time to time as Den-Mat may reasonably request.

10.4 Customer Information. On the Effective Date, Remedent shall deliver to Den-Mat a list
of all of its customers for Products in the Territory and all related records of such customers, a
list of all open orders and a list of all active customer activities unless, and then only to the
extent, prohibited by applicable law. Similarly on each date an Excluded Market or the China
Market becomes part of the Territory under this Agreement, Remedent shall deliver to Den-Mat a list
of all of its customers for Products in the Excluded Market or the China Market, as the case may
be, that is becoming part of the Territory and all related records of such customers, a list of all
open orders and a list of all active customer activities unless, and then only to the extent (a)
prohibited by applicable law or (b) prohibited by confidentiality obligations in the related
distribution agreement. All such open orders will become orders of Den-Mat, for which Den-Mat will
assume collection obligations and for which a royalty (if any) will be payable to Remedent pursuant
to Section 6.

-21-

 

10.5 Executive Support. At least once per calendar quarter Nicholas Teti and Stephen
Ziskind of Den-Mat and Guy De Vreese of Remedent, or the successors to their respective positions,
shall meet in a mutually agreed upon location to discuss business and marketing issues related to
the Products and the relationship between Remedent and Den-Mat.

10.6 Advertising. Remedent shall not mail, publish or broadcast any advertisement or other
promotional materials related to the Products unless either: (a) such advertisement or other
promotional materials are mailed, published and broadcast solely within one or more territories in
which Den-Mat does not have sole and exclusive distribution rights with respect to the Products
(and it is not expected that such advertisement or other promotional materials will be
redistributed outside of such territories) or (b) Den-Mat has given its prior written approval to
such advertisement or other promotion; provided, however, Remedent or its
distributors or subcontractors shall have a right to mail, publish, or broadcast any advertisement
or other promotional materials in the Excluded Markets and in the China Market (including the right
to promote the product via the world wide web). Remedent shall cooperate with Den-Mat, at
Remedent’s own expense and in such manner as Den-Mat may reasonably request, to either (a) continue
to maintain the GlamSmile web site and to make such changes therein as Den-Mat may from time to
time request or (b) transfer to Den-Mat all of Remedent’s right, title and interest in and to such
web site and the right to maintain and modify such web site.

10.7 Regulatory Matters. Den-Mat shall be responsible for obtaining all regulatory
approvals required for it to act as a distributor of the Products in each jurisdiction where the
nature of its activities requires such approval to be obtained. Remedent shall be responsible for
obtaining all regulatory approval required for it to manufacture the Products in each jurisdiction
where such approval is required to be obtained. Each of Remedent and Den-Mat shall provide to the
other, upon reasonable request, materials in their respective possession and access to their
respective employees, in each case that the requesting Party reasonably determines to be relevant
to any regulatory approval sought or required to be obtained by it with respect to the manufacture,
distribution, marketing or sale of the Products.

11. Change of Control.

11.1 Option to Receive Exit Fee. If a Change of Control of Den-Mat is consummated prior to
the third anniversary of the commencement of the Guaranty Period, Den-Mat or the Person acquiring
control of Den-Mat will give notice to Remedent, promptly (and in any event within thirty (30)
days) after the occurrence of such Change of Control (a “Change of Control Notice”), which
Change of Control Notice shall state a Change of Control has occurred, state the amount of the Exit
Fee that would be payable in connection with such Change of Control, if any, and further state
whether Den-Mat (or such Person) desires to terminate the Agreement. If such Change of Control
Notice does not state Den-Mat (or such Person) desires to terminate this Agreement, then within
fifteen (15) days after receipt of the Change of Control Notice, Remedent shall deliver a notice to
Den-Mat either (a) electing to receive an exit fee (the “Exit Fee”) as described in this
Section 11.1 or (b) electing to continue this Agreement in accordance with its other terms.
If Remedent does not notify Den-Mat that Remedent elects to receive the Exit Fee during such
fifteen (15) day period, Remedent shall be deemed to have waived its right to receive the Exit Fee.
If Remedent delivers a notice to Den-Mat during such fifteen (15) day period that it elects to
receive the Exit Fee, then Den-Mat shall pay the Exit Fee to Remedent as

-22-

 

provided in Section 11.2. The provisions of this Section 11 will only apply to the
first Change of Control consummated after the Effective Date. If the Change of Control Notice
states that Den-Mat (or such Person) desires to terminate this Agreement, such notice shall be
deemed a notice of termination pursuant to Sections 13.3 and 7.5.1., but shall not
relieve Den-Mat of its financial obligations to make the minimum payments it is required to make to
Remedent during any unexpired Guaranty Period.

11.2 Calculation of Exit Fee.

     11.2.1 Subject to Section 11.2.3, if a Change of Control is consummated during the
Guaranty Period and on or before the second anniversary of the commencement of the Guaranty Period,
the Exit Fee shall equal [***].

     11.2.2 Subject to Section 11.2.3, if a Change of Control is consummated during the
Guaranty Period and after the second anniversary of the commencement of the Guaranty Period but on
or before the third anniversary of such commencement date, the Exit Fee shall equal [***].

     11.2.3 If a Change of Control is pursuant to clause (i) or (ii) of the
definition of a Change of Control and involves less than all of the ownership interests of DLJ
Merchant Banking Partners and its Affiliates, the Exit Fee calculated pursuant to Section
11.2.1 or 11.2.2, as the case may be, shall be reduced by multiplying the amount
calculated pursuant to Section 11.2.1 or 11.2.2, as the case may be, by the
fraction whose numerator is the percentage of the ownership interests of DLJ Merchant Banking
Partners and its Affiliates being transferred in such Change of Control and whose denominator is
one hundred percent (100%).

     11.2.4 If Remedent delivers a notice electing to receive an Exit Fee pursuant to Section
11.1, such Exit Fee shall be payable by Den-Mat within ten (10) Business Days after receipt of
such notice from Remedent. The Exit Fee shall be paid to Remedent, at the option of Den-Mat,
either in cash or in the same form or forms of consideration as Den-Mat or its equity holders
received in such Change of Control transaction (and if Den-Mat elects this option and more than one
form of consideration was received by Den-Mat or its equity holders in such Change of Control
transaction, the Exit Fee shall be paid to Remedent in such forms of consideration in the same
relative proportion as was paid to Den-Mat or its equity holders).

11.3 Effect of Payment of Exit Fee.

     11.3.1 Royalties Terminate. If the Exit Fee is paid to Remedent, (a) the obligation
to pay amounts to Remedent pursuant to Section 6.3 or 6.4 shall terminate effective
as of the effective date of such Change of Control, (b) the price per Unit/Tooth pursuant to
Section 7.1.4 shall be reduced by [***] per Unit/Tooth effective as of the date
of such Change of Control and (c) the amount of any payments from Den-Mat to Remedent pursuant to
Section 6.3 or 6.4 made after the effective date of such Change of Control and [***]
per Unit/Tooth purchased by Den-Mat pursuant to Section 7.1 after the
effective date of such Change of Control shall either be offset against the payment by Den-Mat of
the Exit Fee or directly refunded by Remedent to Den-Mat concurrently with payment of the Exit Fee.
Payment of the Exit Fee, however, shall not terminate the Guaranty Period.

-23-

 

     11.3.2 Royalty-Free License. If the Person or Persons who acquire control of Den-Mat
in the Change of Control transaction with respect to which the Exit Fee is paid desire to
manufacture, market, distribute, license and sell the Products other than through Den-Mat and its
sublicenses and subcontractors, Remedent shall grant to Den-Mat or to such Person or Persons, as
the case may be, a royalty-free license equivalent to those granted in Sections 2,
3 and 4 of this Agreement (reflecting no payments pursuant to Sections 6.3
and 6.4 and a reduction in the price per Unit/Tooth under Section 7.1.4 of [***]
per Unit/Tooth) in exchange for the Exit Fee, except for purchases pursuant to Section
7.1.3, which shall be at mutually agreed upon prices.

12. Payment Terms, Taxes and Audits.

12.1 Payment. All payments due under this Agreement to Remedent shall be made by bank wire
transfer in immediately available funds to the account of Remedent designated on Schedule
12.1 or such other account designated by notice from Remedent to Den-Mat from time to time.
All payments hereunder shall be in the legal currency of the United States of America, and all
references to “$” or “Dollars” shall refer to United States dollars. If any currency conversion
shall be required in connection with the calculation of amounts payable hereunder, such conversion
shall be made in a manner consistent with Den-Mat’s normal practices used to prepare its audited
financial statements for external reporting purposes; provided that such practices use a
widely accepted source of published exchange rates. Any payment under this Agreement shall be due
on such date as specified in this Agreement and, in the event that such date is not a Business Day,
then the next succeeding Business Day.

12.2 Taxes.

     12.2.1 Den-Mat. Den-Mat shall be responsible for all taxes, duties, tariffs and/or
license fees (“Taxes”) imposed with respect to (a) the Products after title and possession
transfer to Den-Mat, (b) Den-Mat’s marketing, distribution and sales of Products and (c) Den-Mat’s
performance of its obligations under this Agreement, and Den-Mat shall pay all such Taxes in
accordance with the regulations of any applicable taxing authority and applicable law

     12.2.2 Remedent. Remedent shall be responsible for all Taxes imposed upon it with
respect to (a) the Products and related raw materials before title and possession transfer to
Den-Mat, (b) Remedent’s manufacture and sale of Products and (c) Remedent’s performance of its
obligations under this Agreement, and Remedent shall pay all such Taxes for which it is responsible
in accordance with the regulations of any applicable taxing authority and applicable law.

12.3 Audit. Upon not less than sixty (60) days’ prior written notice to Den-Mat, Remedent
shall have the right, at its expense, to have an internationally recognized independent public
accounting firm which is reasonably acceptable to Den-Mat examine during normal business hours the
books and records of Den-Mat and its Affiliates to the extent necessary to verify the accuracy of
any amount paid to Remedent under this Agreement; provided, however, that (a) such
examinations shall not be conducted more frequently than annually, (b) no such examination may be
of a period previously examined and (c) such firm executes and delivers to Den-Mat and its
Affiliates prior to any such examination a written agreement in form and substance reasonably
acceptable to Den-Mat pursuant to which such firm agrees to disclose to

-24-

 

Remedent only the final results of such examination and not the information (including resale price
lists and actual resale prices), books, records, workpapers or materials used to determine such
final results. Den-Mat shall retain its books and records necessary to verify such royalty amounts
for a period of not less than three (3) years. Any examination of Den-Mat’s books, records and
royalty calculations under this Section 12.3 shall be at Remedent’s expense;
provided, however, that if it is determined that the payment of royalties by
Den-Mat with respect to any period reviewed by Remedent is understated by five percent (5%) or
more, Den-Mat shall reimburse to Remedent costs of such examination.

13. Term and Termination.

13.1 Term. This Agreement shall remain in effect unless and until terminated as set forth
in this Section 13.

13.2 Termination for Cause.

     13.2.1 By Remedent. This Agreement may be terminated by Remedent: (a) at any time
upon thirty (30) days’ prior written notice to Den-Mat in the event Den-Mat materially breaches any
of its obligations under this Agreement and fails to cure such breach within such thirty (30) day
period (or ten (10) days for an undisputed payment obligation); (b) immediately upon notice of
termination to Den-Mat if an involuntary or voluntary proceeding shall have been instituted in a
court having jurisdiction seeking a decree or order for relief in respect of Den-Mat under any
applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or for the
appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar
official) of Den-Mat, or for any substantial part of its property, or for the winding-up or
liquidation of its affairs, or Den-Mat fails generally to pay its debts as they become due, or
takes any corporate action in furtherance of any of the foregoing; or (c) immediately upon notice
of termination to Den-Mat if Den-Mat breaches its payment obligation under Section 6.1.1.

     13.2.2 By Den-Mat. This Agreement may be terminated by Den-Mat: (a) at any time upon
thirty (30) days’ prior written notice to Remedent (subject to reduction under the circumstances
described in Section 19.3) in the event of Remedent materially breaches any of its
obligations under this Agreement and fails to cure such breach within such thirty (30) day period;
(b) immediately upon notice of termination delivered to Remedent if an involuntary or voluntary
proceeding shall have been instituted in a court having jurisdiction seeking a decree or order for
relief in respect of Remedent under any applicable bankruptcy, insolvency or other similar law now
or hereafter in effect, or for the appointment of a receiver, liquidator, assignee, custodian,
trustee, sequestrator (or similar official) of Remedent, or for any substantial part of its
property, or for the winding-up or liquidation of its affairs, or Remedent fails generally to pay
its debts as they become due, or takes any corporate action in furtherance of any of the foregoing,
(c) immediately upon notice of termination to Remedent if the Guaranty Period does not commence on
or before March 1, 2009, (d) immediately upon notice of termination to Remedent if (i) during any
two (2) contiguous thirty (30) day periods or (ii) in any three (3) non-overlapping thirty (30) day
periods in a period of 365 days, in each case after the commencement of the Guaranty Period, more
the [***] of Products ordered by Den-Mat from Remedent in such thirty (30) day period are not
delivered to Den-Mat or the proper recipient thereof within the delivery periods required by
Section 8.1 (and for purposes of clarity, a Non-Conforming Product

-25-

 

shall be deemed not to have been delivered) or (e) immediately upon notice of termination to
Remedent if at any time after the commencement of the Guaranty Period Remedent fails to deliver, or
cause to be delivered, within thirty (30) days after an order for Product is delivered to Remedent
or Soca Networks Pte. Ltd., the Product so ordered (and for purposes of this clause (e), a
Non-Conforming Product shall be deemed not to have been delivered (except that with respect to any
Non-Conforming Product only, such thirty (30) day period shall be extended by a number of days
equal to the number of days, if any, that (A) the period between the delivery date by Remedent or
Soca Networks Pte. Ltd. and the date Remedent or Soca Networks Pte. Ltd. is notified the product
delivered is a Non-Conforming Product exceeds (B) seven (7) days)). As an alternative to any such
termination of this Agreement upon the occurrence of any of the events described above in this
Section 13.2, upon the occurrence of such event Den-Mat may deliver a notice that it is
terminating only its required purchase obligations and Remedent’s required supply obligations under
Section 7, and thereafter this Agreement shall continue until terminated in accordance with
its terms except all such purchase and supply obligations shall be treated as having been satisfied
without the requirement for further action by the Parties.

13.3 Termination for Convenience. Den-Mat may terminate this Agreement, in its discretion,
concurrently with its termination of the Guaranty Period pursuant to Section 7.5.1 if
Den-Mat’s notice of termination of the Guaranty Period states it is also electing to terminate this
Agreement. After the end of the Guaranty Period, either Party may terminate this Agreement, in its
discretion, for any reason upon not less than sixty (60) days’ prior written notice to the other
Party, which notice shall state the effective date of such termination. Such notice may be
delivered before the end of the Guaranty Period by Den-Mat, but if delivered before the end of the
Guaranty Period, such termination shall become effective upon the latest of (a) the date sixty (60)
days after delivery of such notice to Remedent, (b) the date of termination set forth in such
notice and (c) the end of the Guaranty Period.

13.4 Sell-Off Period. Upon the expiration of this Agreement pursuant to Section
13.3 or Section 19 or termination of this Agreement by Den-Mat in accordance with
Section 13.2.2 (but not upon a termination by Remedent in accordance with Section
13.2.1), Den-Mat shall be permitted to consummate sales in process (including the manufacture
and sale to complete open orders), and make sales of Products in transit or in its inventory as of
the date of expiration or termination for the duration of the Sell-Off Period. Upon the conclusion
of the Sell-Off Period, Den-Mat shall promptly, but in no event later than fifteen (15) days after
the end of the Sell-Off Period, return to Remedent all unsold Products and Remedent shall acquire
such Products from Den-Mat at Den-Mat’s cost for such Products. If Remedent terminates this
Agreement in accordance with Section 13.2.1, it may request an inventory count from Den-Mat
and access for a physical inspection of the Products, and Den-Mat will provide such access and
inventory count promptly (and in any event within ten (10) Business Days) after receiving such
request. Within ten (10) Business Days after receiving such inventory count, Remedent shall
deliver a notice to Den-Mat electing either to permit Den-Mat to continue to sell Products during
the Sell-Off Period or electing to acquire all such Products then held by Den-Mat at Den-Mat’s
cost. If Remedent exercises the Sell-Off option, then upon conclusion of the Sell-Off Period
Den-Mat shall promptly, and in no event later than fifteen (15) days after the end of the Sell-Off
Period, return to Remedent all unsold Products manufactured by Remedent and Remedent shall acquire
such Products from Den-Mat at Den-Mat’s cost.

-26-

 

13.5 Survival. The provisions of Sections 1, 12.2, 12.3,
13.4, 13.5, 17, 18 and 20 shall survive any termination of
this Agreement, and termination of this Agreement shall not release any Party from liability to the
other Parties for any breach of this Agreement occurring or arising prior to such termination.

14. Representations and Warranties.

14.1 Representations and Warranties of Remedent. As of the Effective Date, Remedent
represents and warrants to Den-Mat as follows:

     14.1.1 Organization. Remedent Nevada is a duly organized corporation, validly
existing and in good standing under the laws of the State of Nevada and has the corporate power and
authority to conduct its business as it is currently conducted by it and to own, operate and lease
its assets. Remedent Belgium is a duly organized corporation, validly existing and in good
standing under the laws of Belgium and has the corporate power and authority to conduct its
business as it is currently conducted by it and to own, operate and lease its assets. Each of
Remedent Nevada and Remedent Belgium is duly licensed or qualified to do business as a foreign
corporation and is in good standing in each jurisdiction in which it is required to be so licensed
or qualified, except where the failure to be so qualified would not have a material adverse effect
on Remedent Nevada, Remedent Belgium, their respective businesses or their collective ability to
fulfill their obligations under this Agreement.

     14.1.2 Authorization. Each of Remedent Nevada and Remedent Belgium has all required
power and authority to enter into this Agreement and the other agreements, documents and
instruments contemplated by this Agreement to which it will be a party (collectively, the
“Remedent Transaction Documents”), to perform their respective obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby, including the
appointments and grants set forth in this Agreement. The execution and delivery of this Agreement
and the other Remedent Transaction Documents to which either Remedent Nevada or Remedent Belgium is
a party and the consummation of the transactions contemplated hereby and thereby have been duly
authorized by directors and, to the extent required by applicable law or otherwise, by stockholders
entitled to vote thereon of Remedent Nevada or Remedent Belgium, as applicable, and no other
corporate action or approval by Remedent Nevada or Remedent Belgium, as applicable, is necessary
for the execution, delivery or performance of this Agreement or such other Remedent Transaction
Documents by Remedent Nevada or Remedent Belgium, as applicable. This Agreement has been, and each
of the other Remedent Transaction Documents to which Remedent Nevada or Remedent Belgium is a party
will be when executed and delivered in accordance with the terms and conditions hereof, duly
executed and delivered by Remedent Nevada or Remedent Belgium, as applicable, and this Agreement
is, and each of the other Remedent Transaction Documents to which Remedent Nevada or Remedent
Belgium, as applicable, is a party will be when executed and delivered in accordance with the terms
and conditions hereof, a valid and binding obligation of Remedent Nevada or Remedent Belgium, as
applicable, enforceable against Remedent Nevada or Remedent Belgium, as the case may be, in
accordance with each of its terms, except as such enforceability may be limited by (i) bankruptcy,
insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, relating
to or limiting creditors’ rights generally and (ii) general principles of equity (whether
considered in an action in equity or at law).

-27-

 

     14.1.3 Compliance with Laws. Neither Remedent Nevada nor Remedent Belgium is in
violation of any applicable Law which would reasonably be expected to have a material adverse
impact on its business, its assets or its ability to fulfill its obligations under this Agreement.
Neither Remedent Nevada nor Remedent Belgium has received any written or, to the Knowledge of
Remedent, oral notice from any Governmental Authority to the effect that either Remedent Nevada or
Remedent Belgium is not in compliance with any applicable Law. To the Knowledge of Remedent, no
investigation, review or other Proceeding by any Governmental Authority with respect to either of
Remedent Nevada or Remedent Belgium in relation to any actual or alleged violation of Law is
pending or, to the Knowledge of Remedent, threatened, nor has either Remedent Nevada or Remedent
Belgium received any written or, to the Knowledge of Remedent, oral notice from any Governmental
Authority indicating an intention to conduct any such investigation, review or other Proceeding.
None of Remedent Nevada, Remedent Belgium, any of their respective assets or properties, or any of
their respective directors, officers or stockholders in their capacities as such, is a party to any
consent decree, Order or similar restriction that restricts the conduct of business by Remedent
Nevada or Remedent Belgium or which would otherwise reasonably be expected to have a material
adverse impact on the ability of Remedent Nevada or Remedent Belgium to conduct their respective
businesses.

     14.1.4 No Conflicts; Consents. Neither the execution and delivery of this Agreement
or the other Remedent Transaction Documents by Remedent Nevada or Remedent Belgium, nor the
consummation by them of the transactions contemplated hereby and thereby, nor the fulfillment by
Remedent Nevada and Remedent Belgium of any of the terms and conditions hereof and thereof will:
(a) violate any applicable Law or any Order applicable to Remedent Nevada or Remedent Belgium or
any of their respective assets or properties; or (b) conflict with, violate, result in a breach of,
constitute a default under or create an event that, with or without the giving of notice or the
lapse of time or both, will result in the acceleration of, create in any party the right to
accelerate, terminate, modify, or cancel, or result in the loss of a benefit, or require any notice
under any agreement, contract, lease, license, permit, instrument or other arrangement to which it
is a party or by which it is bound or to which any of its assets is subject (or result in the
imposition of any lien upon any of its assets). No notice to or consent of or with any
Governmental Authority, or other Person, is required to be obtained by Remedent Belgium or Remedent
Nevada in connection with its execution and delivery of this Agreement or the performance of its
obligations hereunder.

     14.1.5 Capitalization; Subsidiaries. The authorized capital stock of Remedent Nevada
consists of fifty million (50,000,000) shares of common stock, par value $0.001 per share (the
“Common Stock”), of which an aggregate of eighteen million, nine hundred ninety-five
thousand, nine hundred sixty-nine (18,995,969) shares are issued and outstanding, and ten million
(10,000,000) shares of preferred stock, par value $0.001 per share, of which none are issued and
outstanding. All of the issued and outstanding shares of capital stock of Remedent Nevada have
been duly authorized and validly issued and are fully paid and nonassessable and none of them were
issued in violation of any pre-emptive rights, rights of first offer or first refusal or similar
rights, or in violation of the Securities Act or any other applicable securities law. Except as
set forth on Schedule 14.1.5, there are no outstanding options, warrants or other rights of
any kind to acquire (including securities exercisable or exchangeable for or convertible into) any
shares of capital stock of Remedent Nevada or securities convertible into or

-28-

 

exchangeable or exercisable for any shares of capital stock of Remedent Nevada created by or
on behalf of Remedent Nevada, and Schedule 14.1.5 sets forth the exercise, conversion or
exchange price of each of the foregoing. The issue of the Warrant under this Agreement and the
issue of any securities in connection with the acquisition of Glamtech-USA, Inc. by Remedent,
pursuant to the Rescission Agreement between Remedent Nevada, Remedent Belgium and Glamtech-USA,
Inc. and the Stock Purchase Agreements between Remedent Nevada and each of Doug Cox and Kourosh
Tahmasebi, respectively, will not result in any adjustment to any such exercise, conversion or
exchange price. Remedent Belgium is a wholly-owned subsidiary of Remedent Nevada. Except as set
forth on Schedule 14.1.5, Remedent Nevada has no direct or indirect subsidiaries, and
Remedent Nevada does not own any capital stock of, or other equity interests in, any other Person.

     14.1.6 Remedent Intellectual Property. Schedule 14.1.6 lists each patent,
registered trademark, design mark, service mark and trade name, registered copyright and domain
name, and each application for any of the foregoing, that is included among the Intellectual
Property owned by or licensed to Remedent related to the Products. Except as set forth in
Schedule 14.1.6, (a) Remedent has all right, title and interest in and to the Intellectual
Property related to the Products owned by it, free and clear of all liens or other encumbrances;
(b) there is no claim or notice of infringement of the Intellectual Property rights of any other
Person pending or threatened in writing within the two (2) year period preceding the date hereof,
against Remedent relating to the operation of Remedent’s business; (c) each material item of
Intellectual Property related to the Products owned by Remedent is valid, subsisting, in full force
and effect, has not been abandoned or passed into public domain, and all necessary registration,
maintenance and renewal documentation and fees in connection with such Intellectual Property of
Remedent have been timely filed with the appropriate authorities and paid; (d) to the Knowledge of
Remedent, each material item of Intellectual Property related to the Products licensed to and used
by Remedent is valid, subsisting, in full force and effect, has not been abandoned or passed into
public domain, and all necessary registration, maintenance and renewal documentation and fees in
connection with such Intellectual Property used by Remedent have been timely filed with appropriate
authorities and paid; (e) to the Knowledge of Remedent, no Person is infringing or misappropriating
the Intellectual Property of Remedent except for such infringements or misappropriations that would
not reasonably be likely to have, individually or in the aggregate, a material adverse effect on
Remedent, its business or its ability to fulfill its obligations under this Agreement; (f) no
present or former employee of Remedent has any proprietary, financial or other interest, direct or
indirect, in any material item of the Intellectual Property of Remedent; and (g) Remedent has taken
reasonable precautions to protect trade secrets constituting material Intellectual Property owned
or used by Remedent, including the execution of appropriate agreements. Use by Remedent of the
Intellectual Property owned or licensed by Remedent does not infringe, misappropriate or violate
any Intellectual Property rights of any Person.

     14.1.7 Affiliate Transactions. Except as set forth on Schedule 14.1.7 or on
Remedent Nevada’s Form 10-KSB for the fiscal year ended March 31, 2008, no director or officer of
Remedent, nor any member of any such person’s immediate family nor any Affiliate of Remedent is a
party to any transaction with Remedent, including any contract: (a) providing for the furnishing of
services to or by, (b) providing for the rental of real or personal property to or from, or (c)
otherwise requiring payments to or from any such Person or any Person in which any such Person has
an interest as an equity holder, director, officer, limited liability company

-29-

 

manager or managing director (or functional equivalents of the foregoing), trustee, member or
partner. No assets or properties (whether tangible or intangible) of any of such Person is used by
Remedent in the conduct of its business.

     14.1.8 Significant Contracts. Schedule 14.1.8 contains a list of all
contracts, agreements, indentures, notes, bonds, loans, instruments, leases, conditional sales
contracts, mortgages, licenses, franchise agreements or undertakings, commitments or arrangements
to which Remedent is a party and that are material to the operation of Remedent’s business, as a
whole, which grant any distribution rights related to any of the Products, the Remedent Veneer
Products or the Other Potential Products or which grant any Person any interest in the Intellectual
Property of Remedent or any of its Affiliates related to the Products (collectively, the
“Significant Contracts”). True, correct and complete copies of the Significant Contracts
have been made available to Den-Mat or its agents or representatives. Except as set forth in
Schedule 14.1.8: (a) each Significant Contract is in full force and effect; (b) each
Significant Contract is a valid and binding obligation of Remedent thereto, enforceable against
Remedent and, to the Knowledge of Remedent, the other parties thereto, in accordance with its terms
and (c) no condition exists or event has occurred which, with notice or lapse of time or both,
would constitute a material breach, violation or default by Remedent under any such Significant
Contract, or, to the Knowledge of Remedent, any other party thereto, or give Remedent or, to the
Knowledge of Remedent, any other party thereto, the right to exercise a remedy under, or to
accelerate the maturity or performance of, or to terminate or modify, any Significant Contract.

     14.1.9 Permits. Schedule 14.1.9 sets forth an accurate and complete list of
all material Permits reasonably necessary for the operation of Remedent’s business (collectively,
the “Remedent Permits”). Each of the Remedent Permits is in full force and effect in all
material respects, and Remedent is not in violation of any of the terms, conditions and
requirements of the Remedent Permits, except for such violations that would not reasonably be
expected to, individually or in the aggregate, have a material adverse effect on Remedent, its
business or its ability to fulfill its obligations under this Agreement. Copies of all of the
Remedent Permits have been made available to Den-Mat, which copies are complete and accurate (in
all material respects). There is no Proceeding pending or, to the Knowledge of Remedent,
threatened that: (a) questions or contests the validity of, or seeks the revocation, nonrenewal or
suspension of, any Remedent Permit or (b) seeks the imposition of any material condition,
administrative sanction, modification or amendment with respect to any Remedent Permit. No
consents under any Remedent Permit are required to be obtained in connection with the consummation
of the transactions contemplated by this Agreement.

     14.1.10 Litigation. Except as set forth in Schedule 14.1.10, there is no
Proceeding pending or, to the Knowledge of Remedent, threatened in writing against Remedent that
would reasonably be likely to have, individually or in the aggregate, a material adverse effect on
Remedent, its business or its ability to fulfill its obligations under this Agreement. Except as
set forth in Schedule 14.1.10, Remedent is not subject to any unsatisfied Order entered in
any Proceeding.

     14.1.11 Labor Matters. Except as disclosed in Schedule 14.1.11: (a) Remedent
is not a party to any collective bargaining agreement; (b) there are no strikes, work stoppages,
slowdowns or lockouts pending or, to the Knowledge of Remedent, threatened in writing, which

-30-

 

involve the employees of Remedent; (c) there are no arbitrations or grievances pending against
Remedent; (d) to the Knowledge of Remedent, there is no organizing activity involving the employees
of Remedent pending or threatened in writing by any labor union or group of employees; and (e)
there are no unfair labor practice charges, grievances or complaints pending or, to the Knowledge
of Remedent, threatened against Remedent by or on behalf of any employee of Remedent.

     14.1.12 Product Liability. There are no existing or threatened product liability or
other similar claims against either of Remedent Nevada or Remedent Belgium for products or services
of Remedent Nevada or Remedent Belgium. Neither Remedent Nevada nor Remedent Belgium has received
any statements, citations, decisions or orders by any Governmental Authority stating that any
Product manufactured, sold, shipped, designed, marketed, distributed or otherwise introduced into
the stream of commerce at any time by either or both of Remedent Nevada and Remedent Belgium is
defective or unsafe or fails to meet any standards promulgated by any such Governmental Authority.
To the Knowledge of Remedent, there are no material latent or overt design, manufacturing or other
defects in any Product. All Products sold by Remedent in its business comply in all material
respects with all industry and trade association standards and legal requirements, if any,
applicable to such Products, including consumer product, manufacturing, labeling, quality and
safety laws of the United States and each state in which the Products are sold and each other
jurisdiction (including foreign jurisdictions) in which the Products are sold.

     14.1.13 Insurance. Remedent maintains adequate policies of insurance to provide
coverage to either or both of Remedent Nevada and Remedent Belgium, their assets and their
businesses, and all such policies (a) are currently valid, outstanding and enforceable, (b) provide
adequate coverage for the business and assets of Remedent; and (c) are sufficient for compliance
with all applicable Laws and Significant Contracts; and neither Remedent Nevada nor Remedent
Belgium has received any written, or to the Knowledge of Remedent, oral notice of cancellation,
termination, non-renewal or reduction in or refusal of coverage under any policy of insurance
within the past three (3) years or other indication that any insurance policy is no longer in full
force and effect or will not be renewed and no material dispute with any insurance carrier exists
with respect to the scope of any insurance coverage.

     14.1.14 SEC Filings. Since March 31, 2008, Remedent Nevada has filed all reports,
schedules, forms, statements and other documents required to be filed by it with the SEC pursuant
to the reporting requirements of the Exchange Act (all of the foregoing filed prior to the date
hereof and after March 31, 2008, and all exhibits included therein and financial statements and
schedules thereto and documents incorporated by reference therein, being hereinafter referred to as
the “SEC Documents”). As of their respective dates, the SEC Documents complied with the
requirements of the Exchange Act or the Securities Act, as the case may be, and the rules and
regulations of the SEC promulgated thereunder applicable to Remedent Nevada, and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not
misleading.

-31-

 

     14.1.15 Disclosure. No representation, statement, or information provided by or on
behalf of either of Remedent Nevada or Remedent Belgium, which is contained in this Agreement, any
of the schedules to this Agreement or any of the other Remedent Transaction Documents, contains or
will contain any untrue statement of a material fact or omits or will omit a material fact
necessary to make the information contained therein not misleading.

For purposes of this Section 14, it shall be assumed that the acquisition of Glamtech-USA,
Inc. by Remedent, pursuant to the Rescission Agreement between Remedent Nevada, Remedent Belgium
and Glamtech-USA, Inc. and the Stock Purchase Agreements between Remedent Nevada and each of Doug
Cox and Kourosh Tahmasebi, respectively, has been consummated in accordance with the terms set
forth in such agreements.

14.2 Representations and Warranties of Den-Mat. As of the Effective Date, Den-Mat
represents and warrants to Remedent as follows:

     14.2.1 Organization. Den-Mat is a duly organized limited liability company, validly
existing and in good standing under the laws of the State of Delaware, and has the limited
liability company power and authority to conduct its business as it is currently conducted by it
and to own, operate and lease its assets. Den-Mat is duly licensed or qualified to do business as
a foreign limit liability company and is in good standing (to the extent such concept is applicable
to it) in each jurisdiction in which it is required to be so licensed or qualified, except where
the failure to be so qualified would not have a material adverse effect on Den-Mat, its business or
its ability to fulfill its obligations under this Agreement.

     14.2.2 Authorization. Den-Mat has all required power and authority to enter into this
Agreement and the other agreements, documents and instruments contemplated by this Agreement to
which it will be a party (collectively, the “Den-Mat Transaction Documents”), to perform
its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and
thereby. The execution and delivery of this Agreement and the other Den-Mat Transaction Documents
to which Den-Mat is a party and the consummation of the transactions contemplated hereby and
thereby have been duly authorized by the managers and members of Den-Mat entitled to vote thereon,
and no other limited liability company action or approval by Den-Mat is necessary for the
execution, delivery or performance of this Agreement or such other Den-Mat Transaction Documents by
Den-Mat. This Agreement has been, and each of the other Den-Mat Transaction Documents to which
Den-Mat is a party will be when executed and delivered in accordance with the terms and conditions
hereof, duly executed and delivered by Den-Mat, and this Agreement is, and each of the other
Den-Mat Transaction Documents to which Den-Mat is a party will be when executed and delivered in
accordance with the terms and conditions hereof, a valid and binding obligation of Den-Mat,
enforceable against it accordance with each of its terms, except as such enforceability may be
limited by (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or
hereafter in effect, relating to or limiting creditors’ rights generally and (ii) general
principles of equity (whether considered in an action in equity or at law).

     14.2.3 Compliance with Laws. Den-Mat is not in violation of any applicable Law which
would reasonably be expected to have a material adverse impact on its business, its assets or its
ability to fulfill its obligations under this Agreement. Den-Mat has not received any

-32-

 

written or, to the Knowledge of Den-Mat, oral notice from any Governmental Authority to the
effect that Den-Mat is not in compliance with any applicable Law. To the Knowledge of Den-Mat, no
investigation, review or other Proceeding by any Governmental Authority with respect to Den-Mat in
relation to any actual or alleged violation of Law is pending or, to the Knowledge of Den-Mat,
threatened, nor has Den-Mat received any written or, to the Knowledge of Den-Mat, oral notice from
any Governmental Authority indicating an intention to conduct any such investigation, review or
other Proceeding. None of Den-Mat, any of its assets or properties, or any of its directors,
officers or stockholders in their capacities as such, is a party to any consent decree, Order or
similar restriction that restricts the conduct of business by Den-Mat or which would otherwise
reasonably be expected to have a material adverse impact on the ability of Den-Mat to conduct its
business.

     14.2.4 No Conflicts; Consents. Neither the execution and delivery of this Agreement
or the other Den-Mat Transaction Documents by Den-Mat, nor the consummation by Den-Mat of the
transactions contemplated hereby and thereby, nor the fulfillment by Den-Mat of any of the terms
and conditions hereof and thereof will: (a) violate any applicable Law or any Order applicable to
Den-Mat or any of its assets or properties; or (b) conflict with, violate, result in a breach of,
constitute a default under or create an event that, with or without the giving of notice or the
lapse of time or both, result in the acceleration of, create in any party the right to accelerate,
terminate, modify, or cancel, or result in the loss of a benefit, or require any notice under any
agreement, contract, lease, license, permit, instrument, or other arrangement to which it is a
party or by which it is bound or to which any of its assets is subject (or, except as permitted by
Section 20.4, result in the imposition of any lien upon any of its assets). No notice to
or consent of or with any Governmental Authority, or other Person, is required to be obtained by
Den-Mat in connection with Den-Mat’s execution and delivery of this Agreement or the performance of
its obligations hereunder, excluding notices given and consents obtained prior to the date of this
Agreement.

     14.2.5 Litigation. There is no Proceeding pending or, to the Knowledge of Den-Mat,
threatened in writing against Den-Mat that would reasonably be likely to have, individually or in
the aggregate, a material adverse effect on Den-Mat, its business or its ability to fulfill its
obligations under this Agreement. Den-Mat is not subject to any unsatisfied Order entered in any
Proceeding.

     14.2.6 Insurance. Den-Mat maintains adequate policies of insurance to provide
coverage to it, its assets and its business, and all such policies (a) are currently valid,
outstanding and enforceable, (b) provide adequate coverage for the business and assets of Den-Mat
and (c) are sufficient for compliance with all applicable Laws; and Den-Mat has not received any
written, or to the Knowledge of Den-Mat, oral notice of cancellation, termination, non-renewal or
reduction in or refusal of coverage under any policy of insurance within the past three (3) years
or other indication that any insurance policy is no longer in full force and effect or will not be
renewed and no material dispute with any insurance carrier exists with respect to the scope of any
insurance coverage.

     14.2.7 Labor Matters. (a) Den-Mat is not a party to any collective bargaining
agreement; (b) there are no strikes, work stoppages, slowdowns or lockouts pending or, to the
Knowledge of Den-Mat, threatened in writing, which involve the employees of Den-Mat; (c)

-33-

 

there are no arbitrations or grievances pending against Den-Mat; (d) to the Knowledge of
Den-Mat, there is no organizing activity involving the employees of Den-Mat pending or threatened
in writing by any labor union or group of employees; and (e) there are no unfair labor practice
charges, grievances or complaints pending or, to the Knowledge of Den-Mat, threatened against
Den-Mat by or on behalf of any employee of Den-Mat.

     14.2.8 Securities Act Representations. Den-Mat is an “accredited investor” as that
term is defined under the Securities Act. Den-Mat will acquire the Warrants for investment and not
with a view to the sale or distribution thereof or the granting of any participation therein, and
Den-Mat has no present intention of distributing or selling to others any of such Warrants and the
shares issuable upon exercise thereof or granting any participation therein. Den-Mat is aware of
the limited provisions for transferability of the Warrants and the shares issuable upon exercise
thereof. Den-Mat has no need for liquidity in this investment, can afford a complete loss of the
investment in the Warrants and can afford to hold the investment in the Warrants for an indefinite
period of time. Den-Mat acknowledges the Warrants will bear a restrictive legend.

15. Closing. The closing under this Agreement (the “Closing”) will take place: (a) at the
offices of Kelley Drye & Warren LLP, located at 101 Park Avenue, New York, New York 10178, (b) at
10:00 a.m. (New York time) on August 24, 2008 (the “Closing Date”).

16. Closing Conditions.

16.1 Conditions to the Obligation of Remedent. The obligation of Remedent to consummate
the transactions contemplated by this Agreement in connection with the Closing shall be subject to
the satisfaction by Den-Mat or waiver by Remedent on or prior to the Closing Date of each of the
following conditions (unless waived by Remedent in writing):

     16.1.1 The representations and warranties of Den-Mat contained in Section 14.2 shall
be true and correct in all respects (if qualified by materiality) and shall be true and correct in
all material respects (if not qualified by materiality), as if made at and as of the Closing.

     16.1.2 Den-Mat shall have duly performed and complied in all material respects with all
covenants and agreements contained herein required to be performed or complied with by Den-Mat at
or before the Closing.

     16.1.3 Den-Mat shall have taken such actions as are reasonably necessary to cause each of
Evelyne Jacquemyns and Cyrus Tahmesebi to be appointed as members of the advisory board of Den-Mat
as of the Effective Date.

16.2 Conditions to the Obligation of Den-Mat. The obligation of Den-Mat to consummate the
transactions contemplated by this Agreement in connection with the Closing shall be subject to the
satisfaction by Remedent on or prior to the Closing Date of each of the following conditions
(unless waived by Den-Mat in writing):

     16.2.1 The representations and warranties of Remedent contained in Section 14.1 shall
be true and correct in all respects (if qualified by materiality) and shall be true and correct in
all material respects (if not qualified by materiality), as if made at and as of the Closing.

-34-

 

     16.2.2 Remedent shall have duly performed and complied in all material respects with all
covenants and agreements contained herein required to be performed or complied with by Remedent at
or before the Closing.

     16.2.3 Remedent shall have delivered to Den-Mat an opinion, dated the Closing Date, of
Bullivant Houser Bailey PC substantially in the form attached as Exhibit B.

     16.2.4 Remedent shall have delivered to Den-Mat executed copies of the following: (a) a
Non-Competition Agreement duly executed by Guy De Vreese substantially in the form attached as
Exhibit C hereto (the “De Vreese Non-Competition Agreement”) and (b) a
Non-Competition Agreement duly executed by Evelyne Jacquemyns substantially in the form attached as
Exhibit D hereto (the “Jacquemyns Non-Competition Agreement”).

     16.2.5 Remedent Nevada shall have issued to Den-Mat warrants to purchase up to Three Million,
Three Hundred Seventy-Eight Thousand, Three Hundred Seventy-Nine (3,378,379) shares of Remedent
Nevada’s common stock at an exercise price of $1.48 per share, pursuant to a Warrant substantially
in the form attached as Exhibit E (the “Warrant”) and shall have executed and
delivered to Den-Mat a Registration Rights Agreement substantially in the form attached as
Exhibit F.

     16.2.6 On or prior to the Effective Date, Remedent shall terminate all existing distribution
rights held by other Persons with respect to the Products in the Territory.

17. Confidentiality.

17.1 Confidential Information of Den-Mat. All Confidential Information with respect to
Den-Mat and its Affiliates that is disclosed to Remedent by Den-Mat, its Affiliates or
representatives, whether in physical or intangible form, and all Confidential Information regarding
Den-Mat of which Remedent becomes aware in connection with its performance of manufacturing and
other services on behalf of Den-Mat in connection with this Agreement, shall be held as
confidential by Remedent. Such information shall at all times remain the property of Den-Mat and
Den-Mat shall own and retain all right, title and interest therein and thereto. Remedent shall
hold all Confidential Information in confidence, using the same degree of care to prevent
unauthorized disclosure or access that it uses with its own confidential information of similar
type, and shall not disclose such Confidential Information to others, allow others to access it, or
use it in any way, commercially or otherwise, except in direct furtherance of this Agreement.
Remedent may disclose Confidential Information to its employees and its attorneys, accountants and
other confidential advisors with a need to know such Confidential Information in connection with
this Agreement; provided, however, that all such employees and advisors are bound
by obligations to maintain the confidentiality of the Confidential Information at least as
protective as those set forth in this Agreement. Except as set forth herein, nothing in this
Agreement shall be construed as conveying any other right or license (implied or otherwise) to
Remedent in such Den-Mat Confidential Information.

     17.1.1 Permitted Disclosure. If Remedent is compelled to disclose all or any part of
any Confidential Information by any Governmental Authority, it shall, to the extent practicable and
subject to applicable laws, first give prompt written notice of such request to Den-Mat to

-35-

 

enable Den-Mat to seek a protective order or take other appropriate measures to prevent or
modify the disclosure, and shall, at Den-Mat’s expense, cooperate in such efforts.

     17.1.2 Exclusions. Confidential Information with respect to Den-Mat and its
Affiliates shall not include information if and to the extent Remedent can demonstrate such
information: (a) is or becomes known to the public other than by disclosure by Remedent in
violation of this Agreement; (b) was known to Remedent before disclosure hereunder, without a duty
of confidentiality; (c) was independently developed by Remedent outside of this Agreement and
without reference to or use of any Confidential Information of Den-Mat; or (d) was rightfully
obtained by Remedent from a third party without a duty of confidentiality in favor of Den-Mat.

     17.1.3 Return of Confidential Information. Upon the termination of this Agreement,
Remedent shall promptly return to Den-Mat all Confidential Information with respect to Den-Mat and
its Affiliates and all copies, summaries, excerpts and abstracts thereof then in its possession.
Notwithstanding the foregoing, Remedent may keep one copy of any document requested to be returned
or destroyed in the files of its legal department or outside counsel for record purposes only and
for purposes of ensuring compliance with the terms of this Agreement.

     17.1.4 Injunctive Relief. Remedent acknowledges and agrees that in the event of any
breach or threatened breach of its obligations hereunder with respect to Confidential Information,
damages will not be an adequate remedy and Den-Mat shall be entitled to obtain injunctive relief,
without having to post a bond or other security.

17.2 Confidential Information of Remedent. All Confidential Information with respect to
Remedent and its Affiliates that is disclosed to Den-Mat by Remedent, its Affiliates or
representatives, whether in physical or tangible form, and all Confidential Information regarding
Remedent of which Den-Mat becomes aware in connection with its performance of this Agreement shall
be held as confidential by Den-Mat. Such Confidential Information shall at all times remain the
property of Remedent and Remedent shall own and retain all right, title and interest therein and
thereto, except for the interests granted to Den-Mat as part of the license contemplated by this
Agreement. Den-Mat shall hold all Confidential Information in confidence, using the same degree of
care to prevent unauthorized disclosure or access that it uses with its own confidential
information of similar type, and shall not disclose such Confidential Information to others, allow
others to access it, or use it in any way, commercially or otherwise, except in direct furtherance
of this Agreement. Den-Mat may disclose the Remedent Confidential Information to its employees and
its attorneys, accountants, financing sources and other confidential advisors with a need to know
such Confidential Information in connection with this Agreement or their representation of Den-Mat
generally; provided, however, that all such employees and advisors are bound by
obligations to maintain the confidentiality of such Confidential Information at least as protective
as those set forth in this Agreement. Except as set forth herein, nothing in this Agreement shall
be construed as conveying any other right or license (implied or otherwise) to Den-Mat in such
Remedent Confidential Information.

     17.2.1 Permitted Disclosure. If Den-Mat is compelled to disclose all or any part of
any Remedent Confidential Information by any Governmental Authority, it shall, to the extent

-36-

 

practicable and subject to applicable laws, first give prompt written notice of such request
to Remedent to enable Remedent to seek a protective order or take other appropriate measures to
prevent or modify the disclosure, and shall, at Remedent’s expense, cooperate in such efforts.

     17.2.2 Exclusions. Confidential Information with respect to Remedent and its
Affiliates shall not include information if and to the extent Den-Mat can demonstrate such
information: (a) is or becomes known to the public other than by disclosure by Den-Mat in violation
of this Agreement; (b) was known to Den-Mat before disclosure hereunder, without a duty of
confidentiality; (c) was independently developed by Den-Mat outside of this Agreement and without
reference to or use of any Confidential Information of Remedent; or (d) was rightfully obtained by
Den-Mat from a third party without a duty of confidentiality. Den-Mat may also use and disclose
Confidential Information of Remedent to the extent such information is otherwise permitted to be
used or disclosed by Den-Mat pursuant to other provisions of this Agreement, including to
sub-distributors and subcontractors who agree to maintain the confidentiality thereof on terms
comparable to those set forth in this Section 17.

     17.2.3 Return of Confidential Information. Upon the termination of this Agreement,
Den-Mat shall promptly return to Remedent all Confidential Information with respect to Remedent and
its Affiliates and all copies, summaries, excerpts and abstracts thereof then in its possession.
Notwithstanding the foregoing, Den-Mat may keep one copy of any document requested to be returned
or destroyed in the files of its legal department or outside counsel for record purposes only and
for purposes of ensuring compliance with the terms of this Agreement.

     17.2.4 Injunctive Relief. Den-Mat acknowledges and agrees that in the event of any
breach or threatened breach of its obligations hereunder with respect to Confidential Information,
damages will not be an adequate remedy and Remedent shall be entitled to obtain injunctive relief,
without having to post a bond or other security.

18. Indemnification.

18.1 Indemnification by Den-Mat. Den-Mat shall defend, indemnify and hold harmless
Remedent and its Affiliates and its and their respective officers, directors, members, managers,
employees, agents and representatives from and against any and all claims, judgments, damages,
liabilities, actions, demands, costs, expenses or losses, including reasonable attorneys’ fees and
costs (collectively, “Liabilities”), to the extent resulting from, arising out of, or in
connection with, an act or omission of Den-Mat in connection with performance of its obligations
under this Agreement and the other Den-Mat Transaction Documents, or the breach of any
representation, warranty or covenant made by Den-Mat in this Agreement or any of the other Den-Mat
Transaction Documents.

18.2 Indemnification by Remedent. Remedent shall defend, indemnify and hold harmless
Den-Mat and its Affiliates and its and their respective officers, directors, members, managers,
employees, agents and representatives from and against any and all Liabilities, to the extent
resulting from, arising out of, or in connection with any act or omission by Remedent in connection
with performance of its obligations under this Agreement and the other Remedent

-37-

 

Transaction Documents, or the breach of any representation, warranty or covenant made by Remedent
in this Agreement or any of the other Remedent Transaction Documents.

18.3 IP Indemnity. Remedent shall indemnify Den-Mat and its Affiliates and its and their
respective officers, directors, members, managers, employees, agents and representatives from and
against any and all Liabilities, to the extent resulting from, arising out of, or in connection
with any infringement or alleged infringement of the Products, the Intellectual Property of
Remedent, or any use or application thereof upon any Intellectual Property of any Person. If the
manufacture, distribution, marketing, licensing, sale or use of any Product or Intellectual
Property, as contemplated by this Agreement, is enjoined as a result of any Intellectual Property
claim or judgment, then Remedent, in addition to its other obligations under this Agreement, shall,
at its option, (i) obtain for Den-Mat, at Remedent’s expense, any license required for Den-Mat to
manufacture, market, distribute, license and sell the Products as contemplated by this Agreement,
or (ii) redesign the infringing item or items to be non-infringing, while maintaining the original
function thereof or (iii) replace the infringing item or items with an equivalent, non-infringing
item approved by Den-Mat.

18.4 Indemnification Procedures. A Party seeking indemnification under this Section
18 for itself or any of its Affiliates or any of its or their respective officers, directors,
members, managers, employees, agents and representatives (collectively in this capacity, the
“Indemnified Party”) shall promptly notify the Party from whom indemnification is sought
(in this capacity, the “Indemnitor”) of any Liability in respect of which such Indemnified
Party intends to claim indemnification; provided, however, that the failure to so
notify the Indemnitor shall not affect the Indemnified Party’s rights to indemnification hereunder
except to the extent that the Indemnitor is materially prejudiced by such failure. With respect to
any Liabilities that relate to a third party claim, the Indemnified Party shall permit the
Indemnitor to control the defense of any such Liabilities; provided, however, if
the Indemnified Party reasonably determines that the joint representation of the Indemnified Party
and the Indemnitor by a single counsel would result in a conflict of interest arising out of the
joint representation by counsel selected by the Indemnitor of the interests of the Indemnitor and
the Indemnified Party, the Indemnitor shall be entitled to engage separate counsel to represent the
Indemnified Party (at the Indemnitor’s sole cost and expense) and, if the Indemnitor fails to do
so, the Indemnitor shall not be entitled to assume the Indemnified Party’s defense of such
Liability. If the Indemnitor assumes the defense of any Liability, the Indemnitor shall consult
with the Indemnified Party for the purpose of allowing the Indemnified Party to participate in such
defense, but in such case the legal expenses of the Indemnified Party incurred as a result of such
participation shall be paid by the Indemnified Party. With respect to any Proceeding for which the
Indemnitor has assumed the defense of an Indemnified Party, the Indemnitor shall promptly inform
the applicable Indemnified Party of all material developments related thereto, including copying
such Indemnified Party on all pleadings, filings and other correspondence relating thereto. If the
Indemnitor fails to assume and defend a Liability or if, after commencing or undertaking any such
defense, the Indemnitor fails to prosecute such Liability, the Indemnified Party shall have the
right to undertake the defense or settlement thereof. With respect to any Liabilities that relate
to a third party claim, the Indemnified Party shall have the right to settle such Liabilities,
provided the Indemnified Party consents in writing to such settlement, which consent shall not be
unreasonably withheld.

-38-

 

19. Force Majeure Events.

19.1 No Liability. No Party shall be liable for its failure to perform its obligations
under this Agreement to the extent that such performance is made impracticable due to any
occurrence beyond its reasonable control, including, without limitation: acts of God; fires;
floods; wars; sabotage; labor disputes or shortages; governmental laws, ordinances, rules,
regulations, standards or decrees, whether valid or invalid (including, but not limited to, those
related to priorities, requisitions and allocations); inability to obtain raw material, equipment
or transportation; and any other similar occurrences (any such occurrence, a “Force Majeure
Event”). The Parties acknowledge and agree that this Section 19 will not be applicable
to any payment obligations of either party. During a Force Majeure Event that results in Remedent
being unable to supply Products to Den-Mat as provided in this Agreement, the purchase obligations
of Den-Mat in each Contract Year will be reduced pro rata based on the number of days in such Force
Majeure Event divided by 365, and the Contract Year or Contract Period, as the case may be, in
which such Force Majeure Event occurs will not be extended.

19.2 Notification. If a Party fails to perform its obligations under this Agreement as a
result of a Force Majeure Event, such Party shall immediately give written notice to the other
Parties of such Force Majeure Event, which notice shall include a summary of the occurrence, a
reasonably detailed description of the impact on such Party and, if available, a non-binding
estimate of how long such Force Majeure Event will prevent such Party from fulfilling its
obligations under this Agreement. The affected Party shall use all reasonable efforts to remedy
such occurrence or failure to comply with its obligations under this Agreement with all reasonable
dispatch. Subject to Section 19.1 and 19.3 to the extent required by any Force
Majeure Event, the performance by each Party of its obligations under this Agreement shall be
suspended during the continuance of such Force Majeure Event (but for no longer period), and the
time periods for the performance by a Party of its obligations, or the exercise of its rights,
under this Agreement shall be extended for a period of time equal to the duration of such Force
Majeure Event and this Agreement shall otherwise remain unaffected. Notwithstanding the foregoing,
if at any time during the term of this Agreement a Force Majeure Event is remedied or such
compliance is achieved, such Party shall promptly notify the other Parties and any such suspension
shall end.

19.3 Termination. If a Force Majeure Event prevents Remedent from fulfilling its
obligations under this Agreement for a period of sixty (60) days or more, Den-Mat shall have the
right at any time thereafter during the term of this Agreement to terminate this Agreement without
liability to Remedent effective immediately upon notice of termination to Remedent. The right set
forth in this Section 19.3 shall be in addition to, and shall not be exclusive of or
prejudicial to, any other rights, powers or remedies Den-Mat may have under this Agreement, at law,
in equity or otherwise on account of the non-performance (or threatened or anticipated
non-performance) by Remedent of any of its obligations under this Agreement. The exercise of such
right by Den-Mat shall not under any circumstance be deemed to constitute or operate as a waiver of
Den-Mat’s right to require Remedent to fully perform, or a release of Remedent from, its
obligations under this Agreement. As an alternative to any such termination of this Agreement
pursuant to this Section 19.3, in lieu of a notice of termination Den-Mat may deliver a
notice that it is terminating only its required purchase obligations and Remedent’s required supply
obligations under Section 7 through the scheduled end of the Guaranty Period then in effect
(or, if such notice is delivered after the third (3rd) anniversary of the commencement
of the

-39-

 

Guaranty Period, the scheduled end of the Contract Year then in effect), and thereafter this
Agreement shall continue until terminated in accordance with its terms except all such purchase and
supply obligations shall be treated as having been satisfied through the scheduled end of the
Guaranty Period then in effect (or, if such notice is delivered after the third (3rd)
anniversary of the commencement of the Guaranty Period, the scheduled end of the Contract Year then
in effect) without the requirement for further action by the Parties.

20. Miscellaneous.

20.1 Expenses. Except as otherwise specifically provided for in this Agreement, each Party
shall bear its expenses, costs and fees (including attorneys’, auditors’ and financing fees, if
any) incurred in connection with the transactions contemplated hereby, including the preparation,
execution and delivery of this Agreement and compliance herewith.

20.2 Further Actions. Subject to the terms and conditions of this Agreement, each Party
shall execute and deliver such certificates and other documents and take such actions as may
reasonably be requested by any other Party in order to effect the transactions contemplated by this
Agreement.

20.3 Notices. All notices, requests, demands, waivers and other communications required or
permitted to be given under this Agreement shall be in writing and shall be deemed to have been
duly given if: (a) delivered personally; (b) mailed, using certified or registered mail with
postage prepaid; or (c) sent by next-day or overnight mail or delivery using an internationally
recognized overnight courier service, as follows:

	 	 	 
	To Remedent Nevada or Remedent Belgium:

	 	 Remedent, Inc. or Remedent, N.V.
	 

	 	 Xavier De Cocklaan
	 

	 	 42,9831
	 

	 	 Deurle, Belgium
	 

	 	 Attn: Guy De Vreese
	 
	 	 
	with a copy (which shall not constitute 

notice) sent to:

	 	 Bullivant Houser Bailey PC
 1415
L Street, Suite 1000
 Sacramento,
California 95814
	 

	 	 Attn: Scott E. Bartel
	 
	 	 
	To Den-Mat:

	 	 Den-Mat Holdings, LLC
	 

	 	 2727 Skyway Drive
	 

	 	 Santa Maria, California 93455
	 

	 	 Attn: Chief Executive Officer

-40-

 

	 	 	 
	with a copy (which shall not

	 	 Kelley Drye & Warren LLP
	constitute notice) sent to:

	 	 400 Atlantic Street, 13th Floor
	 

	 	 Stamford, Connecticut 06901
	 

	 	 Attn: John T. Capetta

or, in each case, at such other address as may be specified in writing to the other Parties in
accordance with this Section 20.3.

     All such notices, requests, demands, waivers and other communications shall be deemed to have
been received: (a) if by personal delivery, on the day of such delivery; (b) if by certified or
registered mail, on the third (3rd) Business Day after the mailing thereof; or (c) if by
next-day or overnight mail or delivery, on the day delivered.

20.4 Binding Effect; Assignment. This Agreement shall be binding upon and inure to the
benefit of the Parties and their respective successors and permitted assigns. Remedent shall not
assign this Agreement either in whole or in part without the prior written consent of Den-Mat.
Den-Mat shall not assign this Agreement either in whole or in part without the prior written
consent of Remedent; provided, however, that Den-Mat shall have the right to assign
this Agreement either in whole or in part to Affiliates of Den-Mat, to any successor to all or
substantially all of Den-Mat’s business and in connection with a collateral assignment to lenders.
Any attempted assignment or delegation in violation of this Section 20.4 will be void.
Except as expressly set forth in Section 17, nothing in this Agreement, expressed or
implied, is intended or shall be construed to confer upon any Person, other than the Parties and
the successors and assigns permitted by this Section 20.4, any right, remedy or claim under
or by reason of this Agreement.

20.5 Amendment; Waiver. No amendment, modification or discharge of this Agreement, and no
waiver hereunder, shall be valid or binding unless set forth in writing and duly executed by the
Party or Parties against whom enforcement of the amendment, modification, discharge or waiver is
sought; provided, however, that if Den-Mat is the Party against whom enforcement of
any amendment, modification, discharge or waiver is sought, such amendment, modification, discharge
or waiver will only be valid and binding if duly approved by the board of managers of Den-Mat.
Any such waiver shall constitute a waiver only with respect to the specific matter described in
such writing and shall in no way impair the rights of the Party or Parties granting such waiver in
any other respect or at any other time. The waiver by any of the Parties of a breach of or a
default under any of the provisions of this Agreement or a failure to or delay in exercising any
right or privilege hereunder, shall not be construed as a waiver of any other breach or default of
a similar nature, or as a waiver of any of such provisions, rights or privileges hereunder. The
rights and remedies herein provided are cumulative and none is exclusive of any other, or of any
rights or remedies that any Party may otherwise have at law or in equity. Notwithstanding the
foregoing, any amendment pursuant to Sections 2.2.3, 2.4.1 and 3.4.1 shall
be implemented as provided therein.

20.6 Entire Agreement. This Agreement (including the Exhibits and Schedules referred to
herein or delivered hereunder) and the agreements expressly contemplated to be executed and

-41-

 

delivered by the Parties pursuant to this Agreement constitute the entire agreement between the
Parties with respect to the subject matter hereof and supersedes all contemporaneous oral
agreements and all prior oral and written quotations, communications, agreements, understandings of
the Parties (including the letter of intent, dated June 9, 2008, between Den-Mat and Remedent, as
amended, and the Mutual Non-Disclosure and Confidentiality Agreement, dated April___, 2008, by and
among Remedent, Den-Mat and GlamTech-USA Inc.), and written or oral representations of any Party
with respect to the subject matter of this Agreement.

20.7 Severability. If any provision of this Agreement shall be held or declared to be
invalid or unenforceable, such invalid or unenforceable provision shall not affect any other
provision of this Agreement, and the remainder of this Agreement, and each Party’s obligations
hereunder, shall continue in full force and effect as though such provision had not been contained
in this Agreement and, if permitted under applicable rules of instruction and interpretation, such
provision shall be reformed to the extent necessary to render such provision valid and enforceable
and to reflect the intent of the Parties to the maximum extent possible under applicable law.

20.8 Headings. The headings contained in this Agreement are for reference purposes only
and shall not in any way affect the meaning or interpretation of this Agreement.

20.9 Counterparts. This Agreement may be executed in one or more counterparts, all of
which will be considered one and the same agreement and will become effective when one or more
counterparts have been signed by each of the Parties and delivered to the other Parties, regardless
of whether all of the Parties have executed the same counterpart. Counterparts may be delivered
via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so
delivered shall be deemed to have been duly and validly delivered and be valid and effective for
all purposes.

20.10 Governing Law. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES SHALL BE
GOVERNED BY, CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT
GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW RULE THAT WOULD CAUSE THE APPLICATION OR THE LAWS OF
ANY JURISDICTION OTHER THAN THE INTERNAL LAWS OF THE STATE OF NEW YORK TO THE RIGHTS AND DUTIES OF
THE PARTIES.

20.11 Consent to Jurisdiction.

     20.11.1 EACH OF THE PARTIES IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS
PROPERTIES AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF THE COURTS IN THE STATE OF NEW YORK IN THE
COUNTY OF NEW YORK OR THE UNITED STATES OF AMERICA FOR THE SOUTHERN DISTRICT OF NEW YORK AND ANY
APPELLATE COURT THEREFROM (COLLECTIVELY, THE “NEW YORK COURTS”), IN ANY PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR FOR RECOGNITION OR
ENFORCEMENT OF ANY JUDGMENT RELATING THERETO, AND EACH OF THE PARTIES IRREVOCABLY AND
UNCONDITIONALLY AGREES THAT

-42-

 

ALL CLAIMS IN RESPECT OF ANY SUCH PROCEEDING SHALL BE HEARD AND DETERMINED IN THE NEW YORK
COURTS. EACH OF THE PARTIES AGREES THAT A FINAL JUDGMENT IN ANY SUCH PROCEEDING SHALL BE
CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER
MANNER PROVIDED BY LAW.

     20.11.2 EACH OF THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT
MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING
OF VENUE OF ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY IN ANY OF THE NEW YORK COURTS. EACH OF THE PARTIES IRREVOCABLY WAIVES, TO THE
FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH
PROCEEDING IN ANY OF THE NEW YORK COURTS.

20.12 Waiver of Punitive and Other Damages and Jury Trial.

     20.12.1 THE PARTIES TO THIS AGREEMENT EXPRESSLY WAIVE AND FORGO ANY RIGHT TO RECOVER PUNITIVE,
EXEMPLARY OR SIMILAR DAMAGES IN ANY ARBITRATION, LAWSUIT, LITIGATION OR PROCEEDING ARISING OUT OF
OR RESULTING FROM ANY CONTROVERSY OR CLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY.

     20.12.2 EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, TO THE FULLEST
EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY
RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

     20.12.3 EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (a) NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF THE FOREGOING WAIVERS, (b) IT UNDERSTANDS AND HAS
CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (c) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (d) IT HAS
BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 20.12.3.

20.13 No Waiver; Remedies. No Party shall by any act (except by written instrument
pursuant to Section 20.5), delay, indulgence, omission or otherwise be deemed to have
waived any right or remedy hereunder or to have acquiesced in any default in or breach of any of
the

-43-

 

terms and conditions of this Agreement. No failure to exercise, nor any delay in exercising on the
part of any Party, any right, power or privilege hereunder shall operate as a waiver thereof. No
single or partial exercise of any right, power or privilege hereunder shall preclude any other or
further exercise thereof or the exercise of any other right, power or privilege.

20.14 No Limitation on Competitive Activities. Nothing in this Agreement shall, or shall
be construed to, limit in any way Den-Mat’s right and ability to manufacture, market, distribute,
license and sell any other products or services in the Territory, regardless of whether such other
products or services compete with the Products.

20.15 No Partnership or Joint Venture. Nothing in this Agreement shall be construed as (a)
giving any Party any rights as a partner in or owner of the business of the other Parties, (b)
entitling a Party to control in any manner the conduct of the other Parties’ business, or (c)
making any Party a joint venturer, joint employer, principal, agent, or employee of the other
Parties. Except as expressly set forth in this Agreement or in any of the agreement or instruments
contemplated hereby, no Party shall have, nor shall it represent itself as having, the power to
make any contracts or commitments in the name of or binding upon any of the other Parties.

20.16 Jointly Drafted; Review by Counsel. The Parties have participated in the negotiation
and drafting of this Agreement and have had the opportunity to review the Agreement with counsel of
their choosing. In the event an ambiguity or question of intent or interpretation arises, no
presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the
authorship of any of the provisions of this Agreement.

20.17 Specific Performance. Each of the Parties acknowledges and agrees that, in the event
of any breach of this Agreement, the non-breaching Party would be irreparably and immediately
harmed and could not be made whole by monetary damages. It is accordingly agreed that the Parties
(a) shall be entitled, in addition to any other remedy to which they may be entitled at law or in
equity, to compel specific performance of this Agreement; and (b) shall waive, in any action for
specific performance, the defense of the adequacy of a remedy at law.

20.18 Interpretation. The language used in this Agreement shall be deemed to be the
language chosen by the Parties to express their mutual intent and no rule of strict construction
shall be applied against any Party. Unless otherwise expressly specified in this Agreement: (a)
the words “hereof”, “hereby” and “hereunder,” and correlative words, refer
to this Agreement as a whole and not any particular provision; (b) the words “include”,
“includes” and “including”, and correlative words, are deemed to be followed by the
phrase “without limitation”; (c) the word “or” is not exclusive and is deemed to
have the meaning “and/or”; (d) words using the singular or plural number shall also include
the plural or singular number, respectively; (e) the masculine, feminine or neuter form of a word
includes the other forms of such word and the singular form of a word includes the plural form of
such word; (f) references to a Person shall include the permitted successors and assigns thereof;
(g) references made in this Agreement to an Article, Section, Schedule or Exhibit mean an Article
or Section of, or a Schedule or Exhibit to, this Agreement; and (h) all consents and approvals are
in the sole discretion of the Party requested to give such consent or approval, unless otherwise
expressly provided.

-44-

 

20.19 Mitigation. Each Party shall take commercially reasonable efforts to mitigate its
damages in the event of a breach of this Agreement by the other Party.

[remainder of page intentionally left blank; signature page follows]

-45-

 

     IN WITNESS WHEREOF, Remedent Nevada, Remedent Belgium and Den-Mat, by their respective
authorized representatives set forth below, have signed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	REMEDENT, INC.	 	 	 	REMEDENT, N.V.	 	 
	“Remedent Nevada”	 	 	 	“Remedent Belgium”	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Guy De Vreese
 

	 	 
	 	By:
	 	/s/ Guy De Vreese
 

	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Name: Guy De Vreese	 	 	 	Name: Guy De Vreese	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Title: Chairman of the Board	 	 	 	Title: Chief Executive Officer	 	 

DEN-MAT HOLDINGS, LLC

“Den-Mat”

	 	 	 	 	 
	By:

	 	/s/ Nicholas Teti
 

	 	 
	 
	 	 	 	 
	Name: Nicholas Teti	 	 
	 
	 	 	 	 
	Title: Chief Executive Officer	 	 

-46-

 

Schedule 1

Definitions

               (a) “Affiliate” shall mean, with respect to an entity, any entity that Controls, is
Controlled by, or is under common Control with, that entity.

               (b) “Business Day” shall mean any day other than a Saturday, Sunday or any other day
on which commercial banks in New York are authorized or required by law to remain closed.

               (c) “Change of Control” shall mean any: (i) merger, reorganization, consolidation or
other business combination that results in DLJ Merchant Banking Partners or its Affiliates
transferring a majority of their collective equity interests in Den-Mat to any Person
(independently or together with any Affiliates of such Person) other than other Affiliates of DLJ
Merchant Banking Partners, (ii) sale of all or substantially all of the assets of Den-Mat to any
Person (independently or together with any Affiliates of such Person) other than DLJ Merchant
Banking Partners or its Affiliates or (iii) sale by DLJ Merchant Banking Partners and its
Affiliates of a majority of their outstanding membership interests in Den-Mat to any Person
(independently or together with any Affiliates of such Person) other than other Affiliates of DLJ
Merchant Banking Partners.

               (d) “Confidential Information” of any Person shall mean all confidential or
proprietary information of such Person, including financial statements, customer and supplier
lists, reports, marketing studies, and business plans and forecasts, whether written, oral, or in
electronic or other form and whether prepared by such Person, its Affiliates or its
representatives.

               (e) “Contract Period” shall mean the following periods, (a) the first fifteen (15)
months of the Guaranty Period; (b) the subsequent twelve (12) months of the Guaranty Period; (c)
the subsequent nine (9) months of the Guaranty Period and (d) each subsequent twelve (12) month
period thereafter, in each case during which the Guaranty Period is in effect.

               (f) “Contract Year” shall mean the twelve (12) month period commencing on the first
day of the Guaranty Period and on each subsequent anniversary of such date, in each case during
which the Guaranty Period is in effect.

               (g) “Control” (including with correlative meanings, the terms “Controlling,”
“Controlled by” and “under common Control with”) shall mean the possession directly
or indirectly of the power to direct or cause the direction of the management and policies of an
entity, whether through the ownership of voting securities, by trust, management agreement,
contract or otherwise; provided, however, that beneficial ownership of more than
fifty percent (50%) or more of the voting power of an entity shall be deemed to be Control.

               (h) “EBITDA Multiple” shall mean the purchase price paid for Den-Mat in a Change of
Control transaction divided by the EBITDA of Den-Mat for the period of twelve (12) full calendar
months preceding such Change of Control. For purposed of this

 

 

definition “EBITDA” means the consolidated earnings, before interest, taxes, amortization and
depreciation, of Den-Mat as shown on its internal financial statements but (A) before giving effect
to any royalty payments under this Agreement and (B) as adjusted for non-recurring expenses. For
purposes of this definition, the price paid for Den-Mat in such Change of Control shall mean the
purchase price stated in the purchase agreement for such Change of Control transaction, without
giving effect to any escrow holdback, earn-out, post-closing adjustment or other contingent
increase or decrease in the purchase price contemplated by such purchase agreement.

               (i) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

               (j) “Excluded Markets” shall mean the territories identified on Schedule
2.2.1, as the list of such territories shall be modified from time to time pursuant to
Section 2.2.3.

               (k) “Exclusivity Period” shall mean the period commencing on the Effective Date and
ending concurrently with the termination of the Guaranty Period.

               (l) “GlamSmile Non-Tray Technology” shall mean the GlamSmile Technology and Processes
described in Item 2 of Annex A.

               (m) “GlamSmile Product” shall mean all of Remedent’s GlamSmile products, whether now
existing or hereafter developed or acquired, including all of Remedent’s GlamSmile veneer products
(whether made in or out of Trays) made of any material (e.g., hybrid porcelain and full porcelain)
and any private label materials or tools used in the placement of the veneers bearing the GlamSmile
name or brand, and the GlamSmile Technology and Processes incorporated therein, regardless of
whether such products, technology or processes are sold under the name or brand “GlamSmile,”
“Lumineer” or otherwise.

               (n) “GlamSmile Technology and Processes” shall mean (i) the Intellectual Property
provided by Remedent to Den-Mat pursuant to this Agreement and (ii) the processes described in
Annex A, in each case which are used in connection with the development and manufacturing
of the Products and which were not known to Den-Mat prior to the Effective Date other than as a
result of disclosures to Den-Mat by Remedent.

               (o) “GlamSmile Tray Technology” shall mean the GlamSmile Technology and Processes used
to develop and manufacture Trays.

               (p) “Governmental Authority” shall mean any: (a) federal, state, regional, county,
city, municipal or local government, whether foreign or domestic; (b) governmental or
quasi-governmental authority of any nature, including any regulatory or administrative agency,
commission, department, board, bureau, court, tribunal, arbitrator, arbitral body, agency, branch,
official entity or other administrative or regulatory body obtaining authority from any of the
foregoing, including courts and any supra-national organization, state, county, city or other
political subdivision; or (c) other Person exercising or entitled to exercise any administrative,
executive, judicial, legislative, police, regulatory or taxing authority or power of any nature.

 

 

               (q) “Guaranty Period” shall mean the three year period commencing on the first day of
the first calendar month arising after (a) Soca Networks Pte. Ltd.’s manufacturing facility in
[***] has commenced normal operations, (b) Remedent has evidenced to Den-Mat, to the satisfaction
of Den-Mat, the ability to produce [***] Units/Teeth per month at such manufacturing facility and
(c) Remedent has evidenced to Den-Mat, to the satisfaction of Den-Mat, receipt of the
certifications set forth on Schedule 8.7, which period shall be subject to early
termination pursuant to Section 7.5 and 13.2.2 and subject to extension as provided
in Section 7.5.1.

               (r) “Intellectual Property” shall mean a patent, patent application, industrial
design, invention, design, trade secret, idea, work, methodology, technology, innovation, creation,
concept, moral right, development drawing, research, analysis, know-how, experiment, copyright,
trademark, service mark, data, formula, method, procedure, process, system or technique and any
registration, application, right or other grant analogous thereto with respect to any of the
foregoing.

               (s) “Knowledge of Den-Mat” shall mean the actual knowledge of any of the executive
officers of Den-Mat.

               (t) “Knowledge of Remedent” shall mean the actual knowledge of any of the executive
officers of either Remedent Nevada or Remedent Belgium.

               (u) “Law” shall mean any treaty, code, statute, law, rule, regulation, convention,
ordinance, Order, legally binding regulatory policy statement or similar legally binding guidance,
binding directive or decree of any kind of any Governmental Authority, as well as any common law.

               (v) “Net Wholesale Price” shall mean the price Den-Mat charges per Lumineer tooth as
it is invoiced to the end customer from Den-Mat’s perspective (e.g., the dentist, group practice
corporation, distributor), net of any returns, discounts, special pricing, rebates or additional
reasonable price deductions; provided, however, the Net Wholesale Price will regard
only the price of the individual tooth (i.e., if teeth are sold in an arch for a set price in a
Tray, the “price” of the Tray should be split out and deducted).

               (w) “Non-Conforming Product” shall mean any Product shipped by Remedent to Den-Mat
that fails in any respect to conform to the applicable purchase order and the requirements of
Section 8.7.

               (x) “Order” means any judgment, writ, decree, directive, decision, injunction, ruling,
award or order (including any consent decree or cease and desist order) of any kind.

               (y) “Other Potential Products” shall mean all of Remedent’s professional dental
products, and the related Intellectual Property and processes developed or otherwise available for
sale by Remedent (or any of Remedent’s Affiliates) after the Effective Date, but excluding (a) the
GlamSmile Products, (b) professional dental products offered for sale by Remedent on the Effective
Date and (c) improvements to the products referred to in the preceding clause (b) that are
not offered as separate products. For purpose of clarification, Den-

 

 

Mat acknowledges that Other Potential Products does not include non-veneer products for which
the primary distribution channel is the consumer market.

               (z) “Other Products” shall mean all Other Potential Products and Remedent Veneer
Products for which Den-Mat has become a distributor pursuant to Sections 2.3.

               (aa) “Party” shall mean any of Remedent, Inc., Remedent, N.V. or Den-Mat Holdings,
LLC, individually, and “Parties” shall mean all of such Persons collectively.

               (bb) “Permit” shall mean any permit, license, authorization, registration, franchise,
approval, certificate, variance, waiver or other authorization, approval, consent, clearance or
similar right issued, granted or obtained by or from any Governmental Authority.

               (cc) “Person” shall mean any natural person, firm, partnership, association,
corporation, company, trust, business trust, governmental entity or other entity.

               (dd) “Proceeding” shall mean any action, suit, arbitration, mediation, litigation,
hearing, investigation, inquiry or other proceeding of any kind.

               (ee) “Product” shall mean, collectively, the GlamSmile Products and the Other
Products.

               (ff) “SEC” shall mean the Securities and Exchange Commission, and any successor agency
thereto.

               (gg) “Securities Act” shall mean the Securities Act of 1933, as amended.

               (hh) “Sell-Off Period” shall mean a period of ninety (90) days after the date of
expiration or termination of this Agreement.

               (ii) “Territory” means worldwide, except for: (i) the Excluded Markets and (ii) the
China Market.

               (jj) “Tray” shall mean the insertion tray included among the Products into which
Units/Teeth are placed for application to teeth of the end-user patient.

               (kk) “Unit/Tooth” and “Units/Teeth” shall mean the individual units of veneer
in a Den-Mat order, with each such unit of veneer to be applied to a separate tooth and inclusive
of units of veneer to be applied using a Tray or to be applied in any other method.

* * * *

[Index of Defined Terms follows]

 

 

Index of Defined Terms

	 	 	 
	Defined Term	 	Reference
	Agreement
	 	Preamble
	China Market
	 	2.1.2
	Change of Control Notice
	 	11.1
	Closing
	 	15
	Closing Date
	 	15
	Common Stock
	 	14.1.5
	Den-Mat
	 	Preamble
	Den-Mat Facility
	 	6.2.1
	Den-Mat Transaction Documents
	 	14.2.2
	De Vreese Non-Competition Agreement
	 	16.2.4
	Effective Date
	 	Preamble
	Exclusivity Date
	 	2.2.1
	Exit Fee
	 	11.1
	Filing Party
	 	3.5.2
	Force Majeure Event
	 	19.1
	Glam Smile
	 	2.1.3
	Indemnified Party
	 	18.4
	Indemnitor
	 	18.4
	Jacquemyns Non-Competition Agreement
	 	16.2.4
	Liabilities
	 	18.1
	New York Courts
	 	20.11.1
	Notice of Intent to File
	 	3.5.2
	Proposed Remedent Other Products Signing Date
	 	2.3.3
	Proposed Remedent Veneer Signing Date
	 	2.3.1
	Proposed Transfer Date
	 	2.2.3
	Remedent
	 	Preamble
	Remedent Belgium
	 	Preamble
	Remedent Nevada
	 	Preamble
	Remedent Permits
	 	14.1.9
	Remedent Transaction Documents
	 	14.1.2
	Remedent Veneer Product
	 	2.3.1
	SEC Documents
	 	14.1.14
	Significant Contracts
	 	14.1.8
	Subdistributor Agreement
	 	2.1.4
	Taxes
	 	12.2.1
	Upfront Payment
	 	6.1.1
	Warrant
	 	16.2.5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]